CA1339937C - Procedure for obtaining dna, rna peptides, polypeptides, or proteins by recombinant dna techniques - Google Patents

Procedure for obtaining dna, rna peptides, polypeptides, or proteins by recombinant dna techniques

Info

Publication number
CA1339937C
CA1339937C CA000504653A CA504653A CA1339937C CA 1339937 C CA1339937 C CA 1339937C CA 000504653 A CA000504653 A CA 000504653A CA 504653 A CA504653 A CA 504653A CA 1339937 C CA1339937 C CA 1339937C
Authority
CA
Canada
Prior art keywords
polynucleotide sequences
diverse population
amino acid
proteins
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000504653A
Other languages
French (fr)
Inventor
Marc Ballivet
Stuart Alan Kauffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1339937(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of CA1339937C publication Critical patent/CA1339937C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1093General methods of preparing gene libraries, not provided for in other subgroups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/485Epidermal growth factor [EGF] (urogastrone)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1048SELEX
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • C12N15/68Stabilisation of the vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

Procedure for the production of peptides or polypeptides by microbiological means, characterized by the fact that genes which are at least partially composed of stochastic synthetic polynucleotides are produced simultaneously in a common milieu, that the genes thus obtained are introduced into host cells, that the independent clones of the transformed host cells containing these genes are simultaneously cultivated so as to clone the stochastic genes and lead to the production of proteins expressed by each of these stochastic genes, that screening and/or selection is carried out on such clones of transformed host cells in a manner to identify those clones producing peptides or polypeptides having at least one specified property, that the clones so identified are isolated, then grown in a manner so as to produce at least one peptide or polypeptide having the said property.

Description

MARC BALLIVET AND STUART KAUFFMAN ~ 9 '3 ~ 7 PROCEDURE FOR OBTAINING DNA, RNA, K PTIDES, POLYPEPTIDES, OR PROTEINS BY RECOMBINANT
DNA TECHNIQUES

1he present Inventlon has as Its obJect a procedure to obtaln DNA, RNA, peptldes, polypeptldes or protelns, through use of transformed host cells contalnlng genes capable of expresstng these RNAs, peptldes, polypeptldes, or protelns; that Is to say, by utlllzatlon of recomblnant DNA technlques.
The Inventlon alms at the productlon of stochastlc genes or frsgments of stochastlc genes In a fashlon to permlt obtalnlng slmultaneously, after transcrlptlon and translatlon of these genes, a very large number (on the order of at least IO,OOO) of completely new protelns or hybrlds wlth known protelns, In the presence of host cells (bacterlal or eucaryotlc ) contalnlng the genes capable of expresslng these protelns, and to carry out thereafter a selectlon or screen among the sald clones, In order to determlne whlch of them produce protelns wlth deslred propertles, for example structural, enzymatlc, catalytlc, antlgenlc,pharmacologlc, or propertles of llgandlng, and more generally, chemlcal, blochemlcal, blologlcal, etc. propertles.
Thereafter the Inventlon alms at Improvement of the deslred functlon by modlfIcatlon of the sald stochastlc genes, or modlfIcatlon of the products of the sald genes.
The Inventlon equally has as Its alm procedures to obtaln, and then Improve, sequences of DNA or RNA wlth utlllzable propertles, notably chemlcal, blochemlcal, or blologlcal propertles.
It Is clear, therefare, that the Inventlon Is open to a very large number of applIcatlons In very many areas of sclence, Industry and medlclne.
The procedure for productlon of peptldes or polypeptldes accordlng to the Inventlon Is characterlzed In that one produces slmultaneously, In the same medium, genes whlch are at least partlally composed of synthetlc stochastlc polynucleotldes, that one Introduces the genes thus obtalned Into host cells, that one cultlv~tss slmultaneously the Indepsndent clones of the transformed host cells contalnlng these genes In such a manner so as to clone the stochastlc genes and to obtaln the productlon of the protslns expressed by each of these stochastlc genes, that one carrles out selectlon and/or screenlng of the clones of transformed host cells In a manner to Identlfy those clones produclng peptldes or polypeptldes havlng at Isast one deslred actlvlty, that one thereafter Isolates the clones thus Identlfled and that one cultlvates them to produce at least one peptlde or polypeptlde havlng the sald prope~ly. Where Improvment of the desired proper~y Ts sought, the procedure Involves modlflcatlon of the gsnes produclng the Identlfled peptldes, followed by reclonlng the sald genes, and selectlon or screenlng the -2- 133~33~

transformed cells to Identify those produclng at least one peptlde or polypeptlde wlth Improved functton. It also Includes ~odlflcatlon of the proteln product Itself.
In a first means to utlllze thls procedure, stochastlc genes are produced by stochastlc copolymerlzatlon of the four kinds of deoxyphosphonucleotl des A,C,G and T from the two ends of an Inttlally llnerlzed expresslon vector, followed by formation of cohesive ends In such a fashlon as to form a stochastic fIrst strand of DNA constltuted by a molecule of expresslon vector possessing two stochastic sequences whose 3' ends are complementary, followed by the synthesls of the second strand of the stochastlc DNA.
In a second mode to utllize this procedure, stochastic genes are produced by copolymerlzation of ollgonucle~tldes wlthout cohesive ends, in a manner to form fragments of stochastlc DNA, followed by ligat1on of these fragments to a previously llnearlzed expression vector.
The expresslon vector can be a plasmid, notably a bacterlal plasmid. Excellent results have been obtalned using the plasmid pUC8 as the expression vector.
The expression vector can also be vlral i~NA or a hybrld of plasmid and viral i)NA.
The host cells can be prokaryotlc cells such as HB 101 and C 600, or eukaryotic cells.
When utllizing the procedure according to the second mode mentioned above, it is posslble to utilize oligonucleotides which form a group of palindromic octamers.
Partlcularly good resuits are obtained by utilizing the following group of palindromlc octamers:
5' GGAATTCC 3' 5' GGTCGACC 3' 5' CM GCTTG 3' 5' C 'ThTGG 3' 5' CATCGATG 3' It is possible to use oligonucleotides which form a group of paltndromic heptamers.
Good results are obtained utilizing the following group of palindromic heptamers:
5' XTCGCGA 3' 5' XCTGCAG 3' 5' RGGTACC 3' where X = A,G,C,or T, and R = A or T

Accordlng to a method to utillze these procedures whlch is particularly advantageous, one isolates and purifies the . ~ ,~ ~, -3- 133~3~
transformlng DNA of the plasmids from a culture of Independent clones of the transformed host cells obtained by followlng the ~rocedures above, then these plasmids are cut by at least one estrtctlon enzyme correspond1ng to a speciflc restrlctlon cuttlng stte present In the pallndromlc octamers or heptamers but absent from the expresslon vector whlch was utillzed; thls cuttlng Is followed by Inactlvatlon of the restrictlon enzyme, then one simultaneously treats the ensemble of llnearlzed stochastic DNA
fragments thus obtalned wlth T4 DNA ligase, In such a manner to create a new ensemble of DNA contalning new stochastlc sequences, thls new ensemble can therefore contatn a number of stochastic genes larger than the number of genes In the initlal ensemble.
One then utillzes this new ensemble of transformlng DNA to transform the host cells and clone these genes, and finally utlllzes screening and/ or selectlon and isolates the new clones of transformed host cells and finally these are cultivated to produce at least one peptide or polypeptide, for example, a new protein, havlng a deslred property.
Any other means to generate and clone stochastTc DNA sequences so as to obtain their expression as novel peptldes, polypeptldes, or protelns, or thelr expresslon as the novel portion of a fusion protein, followed by screening or selection for a deslred property and obtalnlng at least one clone producing a peptide wlth the desired property, can be used according to the Invention.

The property servtng as the criterlon for selection of the clones of host cells can be the capacity of the peptides or polypeptides, produced by a g1ven clone, to catalyse a glven chemical reaction.
Further, for the production of several peptldes and or polypeptides, the said property can be the capaclty to catalyse a sequence of reactlons leading from an inittal qroup of chemtcal compounds to at least one target compound.
With the alm of producing an ensemble constituted by several or many peptldes and or polypeptldes which are reflexively autocatalytic, the said proprety can be the capacTty to catalyse the synthesis of the same ensemble from amlno acids and/ or ollgopeptldes in an approprlate mllieu.
The satd property can also be the capaclty to modify selectlvely the blologlcal or chemical prcpertles of a glven compound, for example, the capacity to selectlvely modify the catalytlc actlvity of a polypeptTde.
The satd property can also be the capactty to slmulate, Inhiblt, or modlfy at least one blologlcal function of at least one bTologlcally acttve compound, chosen, for example, among t~
hormones, neurotransmitters, adheston factors, growth factors and speclflc regulators of DNA repllcatlon and/or transcrlptlon and/
or translatlon of RNA.
The sald property can equally be the capacit-y of the peptide or polypepttde to blnd to a gtven Itgand.

~li -4- ~33~~337 The Inventlon also has as Its object the use of the peptlde or polypeptlde obtalned by the procedures speclfied above, for the detectlon and/ or the tTtratlon of a llgand.
According to a particularly advantageous mode of utlllzatlon, the crlterlon for selectlon of the clones of transformed host cells Is the capaclty of these peptldes or polypeptides to simulate or modify the effects of a blologtcally actlve molecule, for example, a proteln; screenlng and/or selection for clones of transformed host cells produclng at least one peptide or polypeptlde having this property,ls carried out by preparing or obtaining antlbodies against the the active molecule, then utilizing these antibodies after their purlfication, to identlfy the clones containing peptides or polypepttdes which are bound by the said antibodies agalnst the active molecule, then by cultivatlng the clones thus Identlfied, separatlng and purifying the peptlde or polypeptlde produced by these clones, and finally by submitting the peptide or polypeptide to an In vitro assay to verify that it has the capaclty to simulate or modlfy the effects of the sald molecule.
The capaclty to simulate or modify the effects of the said molecule by the stochastic peptlde can be improved by modificatlon of the gene coding for that peptide, retransformation of the host cells by the modified genes, and selection or screening for those modlfications which improve the desired function. In additlon, the said peptide can be modified chemtcally, or derivatized, to improve Its functton.
According to this means to utilize the procedures according to the Invention, the proper ty servlng as the crTterion of selectton is that of having at least one epitope simTlar to one of the epitopes of a gtven antigen.
The Invention carrtes over to obtatntng polypepttdes by the procedure specified above and uttltzable as chemothera peutically active substances.
In partlcular, in the case where the said anttgen ts EGF, the tnventton permits obtaining polypeptides usable for chemotherapeutic treatment of epltheliomas.
The tnvention also applTes to a use of the procedure specifted above for the preparatton of a vaccTne; the application is charactertzed by the fact that anttbodtes against the pathogenic agent are isolated, for example antibodies formed after injection of the pathogenic agent In the body of an anlmal capable of forming antibodies against this agent, and these antibodies are used to identify the clones producing at least one protein having at least one epitope similar to one of the epitopes of the pathogenic agent, the transformed host cell correspondlng to these clones are cultured to produce these protetns, thts protein~s) Is isolated and purifled from the clones of cells, then thls protein~s) ts used for the productton of a vaccine against the pathogenic agent. The Identified proteins can, as above, be Improved by modiflcattons (eg. mutageniztng) of the stochastic genes coding for the said proteins, retransformation of those genes into appropriate host cells expressing the modifled . ~

13 3~ ~ 37 proteins, rescreening or selectlon of those with improved capaclty to be bound by antlbodies against the initial antlgenic agent, and use of these improved proteins to produce a vaccine.
For example, in order to prepare an anti-HVB vaccine, one can extract and purify at least one capside proteln of the HVB virus inject this proteln into an animal capable of forming antTbodies against thls proteln, recover and purify the antibodies thus formed, utilize these antibodtes to Identify the clones producing at least one protein havlng at least one epitope similar to one of the epitopes of the HVB virus, then cultivate the clones of transformed host cells corresponding to these clones in a manner to produce this proteTn~s), isolate and purify the protein(s) from the culture of these clones of cells and utllize the protein(s) for the production of an anti HV8 vaccine.
According to a variant of the procedure, one tdentifles and isolates the clones of transformed host cells producing peptldes or polypeptides having the property desired, by affinlty chromatography against antibodies corresponding to a protein expressed by the natural part of the DNA hybrid.
For e~ample, in the case where the natural part of the hybrid DNA
contains a gene expressing B- galactosidase, one can advantageously identify and isolate the said clones of transformed host cells by affinity chromatography against anti B
galactosidase antibodies.
After expression and puriflcation of hybrid peptides or polypeptides, one can separate and isolate their novel parts.
According to the inventlon, a means of ut111zing the procedure is to screen or select for novel peptides polypeptides or proteTns catalysing a gTven chemical reaction.
Accordtng to an advantageous means of utilizing the procedures according to the invention, the host cells consist in bacteria such as Escherichia coli whose genome contatns neither the natural gene expressing B galactosidase, nor the EBG gene, that Is to say, Z-,EBG- E coli. The tranformed cells are cultured In the presence of X gal and the indicator IPTG in the medium, and cells posltive for B galactosidase functions are detected;
thereafter, the transformlng DNA is transplanted into an approprlate clone of host cells for large scale culture to produce at least one peptlde or polypeptide with B galactoasTdase actlvlty.
The property serving as the criterion for selection of the tranformed host cells can also be the capacity of the polypeptldes or protelns produced by the culture of these clones to blnd to a glven compound.
This compound can be chosen advantagousely among peptldes, polypeptldes and protelns, notably among protelns regulatlng the transcrlptlon act1vtty of DNA.

1~9~.~7 The Inventlon has also as Its obJect those proteins which are obtained tn the case where the property serving as criterion of selection of the clones of transformed host cells consists in the capacity of these protelns to bind to regulatory proteins controlllng transcription activity or replication of the DNA.
On the cther hand, the said compound which is bound can also be chosen among ONA and RNA sequences.
The Invention has,in addition, as an object obtalning a protein which is able to bind to DNA sequences which act as cis regulatory sequences controlling replication or transcription of neighboring DNA sequences, and by bTnding modify the transcription or replication of the neighborlng DNA sequence. Equally the inventlon has as an object obtaining a protein whtch is able to bind to an RNA sequence and thereby control translation from that RNA or the stability of the RNA.
The alm of the inventlon tncludes utllization of proteins obtained in the second case mentioned to modify the properties of transcrtption or replication of a sequence of DNA, in a cell contalning the sequence of DNA, and expresslng this protein.
The invention has as its object as well a procedure to produce DNA, characterized by stmultaneous production In the same medium, of genes at least partially composed of stochastic synthetic polynucleotldes, that the genes thus obtained are introduced into host cells to produce an ensemble of transformed host cells, that screening and/or selection on this ensemble is carrted out to identify those host cells contatning stochastic sequences of DNA
having at least one desired property , and finally, that the DNA
from the clones of host cells thus identtfied 1s isolated. The properties of the identlfied DNA can be improved by modification of the stochastlc genes, eg through a variety of mutagenesis procedures known in themselves or described below, recloning tnto an approprTate vector, transformation of appropriate host cells, followed by screening or selection for an improved level of the desired property.
The Invention also has as tts object a procedure to produce RNA, characterized by simultaneous production in the same medtum, of genes at least partially composed of stochastlc synthetlc polynucleotides, that the genes thus obtained are introduced Into host cells to produce an ensemble of transformed host cells, that the host cells so produced are cultivated simultaneously, and screenlng and/or selection of thls ensemble is carrled out in a manner to Identify those host cells containing stochastlc sequences of RNA havlng at least one desTred property, and that the RNA be Isolated from the host cells thus identlfled. As above, the properties of the RNA thus Isolated can be improved by modlfIcatlon of the correspondlng stochastlc genes, retransformatlon and reselection or rescreenlng.

The sald property can be, the capaclty to blnd to a given compound, which might be for example a peptlde or polypeptlde or 1339~37 protein, or also the capactty to catalyse a given chemical reaction, or the capacty to be a transfer RNA.

First, we shall describe particularly useful procedures to carry out the synthesis of stochastic genes, and the Introduction of those genes in bacteria to produce clones of transformed bacteria.

I) Direct synthesis on an expression vector.
a) Linearization of the vector.

30 micrograms, that is, approximately 10 molecules of the pUC8 expression vector are linearized by incubatlon for 2 hours at 37PC
with 100 units of the Pstl restriction enzyme in a volume of 300ul of standard buffer for that enzyme. The linearized vector is treated with phenol-chlorofcrm then precipitated in ethanol, taken up in a volume of 30 ul and loaded onto a 0.8% agarose gel in standard TEB bufffer. After mlgration in a field of 3V/cm for three hours, the linearized vector is electro-eluted, precipitated in ethanol, and taken up In 30 ul of water.
b) Stochastic synthesis using the enzyme Terminal Transferase (TdT) 30 ug of the linearized vector are reacted with 30 units of TdT in 300 ul of the appropriate buffer, in the presence of lmM dGTP, lmM
dCTP, 0.3 mM dTTP and 1 mM dATP. The lower concentr ation of dTTP
is chosen in order to reduce the frequency of "stop" codons in the corresponding messenser RNA. A sTmilar result, although somewhat less favorable, can be obtained by utilizing a lower concentratlon for dATP than for the other desoxynucleotide triphosphates, The progress of the polymerization on the 3' extremities of the Pstl sites is followed by analysls on a gel of aliquots taken during the course of the reaction.
When the reactlon attains or passes a mean value of 300 nucleotides added per 3' extremity, it is stoppedand the free nucleotides are separated from the polymer by differential precTpTtatTon or by*passage over a column contaTning a molecular sTeve such as BToogel P60. After concentration by precTpTtatton tn ethanol, the polymers are subjected to a further polymerTzatlon wtth TdT, ftrst tn the presence of dATP, then tn the presence of dTTP. These last two reacttons are separated by a ftltratTon on a gel and are carrted out for short tntervals (30 seconds to 3 minutes) in order to add seque~ially 10 - 30 A
followed by 10 - 30 T to the 3' ends of the polymers.
c) Synthesls of the second strand of the stochastic DNA
Each molecule of vector possessesat the end of the preceeding operatlon, two stochasttc sequences whose 3' ends are complementar~ The mtxture of polymers ts therefore Incubated in condltlons favortng hybrtdizatton of the complementary extrem ities *Trade Mark 13.S~.9937 tl50m~1 NaCI, 10mM Tris-HCI, pH 7.6, lmM EDTA at 65~C for 10 minutes, followed by lowering the temperature to 22~C at a rate of 3 to 4~C per hour. The hybrldlzed polymers are then reacted with units of the large fragment (Klenow) of polymerase 1, in the presence of the four nucleotide triphosphates (20OmM) at 4~C for two hours. This step accomplishes the synthesis of the second strand from the 3 ends of the hybrid polymers. The molecules whlch result from this direct synthesis starting from linearized vector are thereafter utilized to transform competent cells.
d) Transformation of competent clones 100 to 200 ml of competent HB101 of C600 cells at a concentration of lOI~ cells/ml, are incubated with the stochastic DNA
preparation (from above) in the presence of 6mM CaC12, 6 m~l Tris-HCI pH~, 6 m1 MgCI 2 fc,r 30 minutes at 0~C. A temperature shock of 3 minutes at 37~C Ts imposed on the mlxture, followed by the addition of 400 to 800 ml of NZY culture medium, without antibiotics. The transformed culture is Incubated at 37~C fc,r 60 minutes, then diluted to 10 litres by addltion of N~Y medium containing 40 ug/ml of ampicillin. After 3 - 5' hours of incubation at 37~C, the amplified culture is centrTfuged, and the pellet of transformed cells is Iyophilysed and stored at -70~C.
Such a culture contains 3 x 107 to 108 independent transformants, each containing a unique stochasttc gene inserted into the expresslon vector.
Il) Synthesis of stochastlc genes starting from oligonucleotides wlthout cohesive ends.
This procedure is based on the fact that polymerization of judlciously chosen palindromic oligonucleotides permits construction of stochastic genes which have no stop codon tn any of the slx possible reading frames, while at the same tlme assurlng a balanced representation of triplets specifylng all amlno acids. Further, and to avoid a repetitton of sequence motifs in the proteins which result while using only a small number of Initial palindromic oligonucleotides, the oligonucleotldes can contain a number of bases which is not a multiple of three. The example whTch follows describes the use of one of the possible combinations which fulfll these crlter a:
a) Cholce of a group of octamers ~he group of ollgonucleotides followlng:

is composed of 5 palindromes ( thus self complementary sequences) where it Is easy to verify that thelr stochastic polymerization does not generate any stop codons, and speclfles all the amlno aclds.

g Obviously, one can utllize other groups of palindromTc octamers whlch do not generate any "stop" codons and specify all the amino acids found in polypeptldes. Clearly, it is also possible to utilize non palindromlc groups of octamers, or other olisomers, under the condition that their complements forming double stranded DNA are also used. Further it is possible to use more than 5 palindromic octomers.
b) Assembly of an ensemble stochastic genes from a group of octamers.

A mixture conta7ning 5 ug of each of the oligonucleotides indicated above ( previously phosphorylated at the 5' position by a standard procedure) are reacted in a 100 ul volume contaTning 1 mM ATP, 10% polyethYleneglycol, and 100 units of T4 DNA ligase in the appropriate buffer at 13~C for six hours. This step carries out the stochastic polymerization of the oligomers in the double stranded state and wtthout cohesive ends. The resulting polymers are isolated by passage over a molecul'ar sieve (Biogel P60) recovering those with 20 to 100 oligomers. After concentratlon, this fraction is again submitted to catalysis of polymerization by T4 DNA ligase under the conditions described above. Thereafter, as described above, those polymers which have assembled at least 100 oligomers are isolated.
c) Preparation of the host plasmid The pUC8 expression vector is linearized by the Smal enzyme in the appropriate buffer, as describe~ ?hove. The vector linearized by S~a I does not have cohesive ends. Thus the linearized vector is treated by calf Intesting alkaline phosphatase (CIP) at a level of one unit per mTcrogram of vector in the appropriate buffer, at 37~C for 30 minutes. The CIP enzyme is thereafter inactivated by two successive extractions with phenol-choloform. The linearized and dephosphorylated vector is precipitated in ethanol, then redissolved in water at 1 mg/ml.
d) Ligation of stochaatlc genes to the vector Equimolar quantities of vector and polymers are mixed and Incubated In the presence of 1000 units of T4 DNA ligase, 1 mM
ATP, 10~ polyethylene glycol, in the appropriate buffer, for 12 hours at 13~C. Thls step ligates the stochastlc polymers in the expresslon vector and forms double stranded circular molecules which are, therefore, capable of transforming.
Transformation of competent clones.
Transformatlon of competent clones Is carried out in the manner previously descrlbed.
111) Assembly of stochastlc genes startin~ from a group of heptamers.

~ ~39337 l o--Thls procedure dtffers from that just discussed In that it utilizes pallndromic heptamers have variable cohesive ends, in place of the octamers. This has the advantage of allowing assembly of stochastic sequences containlng a smaller number of identlcal motifs.
a) Cholce of a group of heptamers It is possible, as an example, to use the following three palindromic heptamers:
5 ' XTCGCGA 3 ' 5 ' XCTGCAG 3 ' 5 ' RGGTACC 3 ' where X = A,G,C or T and R = A or r, and where polymerization cannot generate any "stop" codons and forms triplets specifying all the amino aclds.
Clearly it Is possible to use other groups of heptamers fulfilling these same conditlons.
b) Polymeriz~tion of a group of heptamers This polymerlzation Is carried out exactly in the fashton described above fcr octamers.
c) Elimtnation of cohesive extremities The polymers thus obtained have one unpaired base on their two 5 ' extremlties. Thus, it is necessary to add the complementary base to the correspondlng 3' extremitles. Thls is carried out as follows: 10 micrograms of the double stranded polymers are reacted with 10 units of the Klenow enzyme, in the presence of the four deoxynucleotide- phosphates (200 m~l) in a volume of 100 ul, at 4~C, for 60 mlnutes. The enzyme is inactivated by phenol chloroform extraction, and the polymers are cleansed of the resldual free nucleotldes by dlfferential precipitation. The polymers are then llgated to the host plasmid (previously linearlzed and dephosphorylated) by following the procedures descrlbed above.
It is to be noted that the two last procedures which were descrlbed utllize palindromlc octamers or heptamers whlch constitute speclflc sltes of certaln restriction enzymes. These sites are absent, for the most part, from the pUC8 expresslon vector. Thus, tt Is posslble to augment conslderably the complexlty of an Inltlal preparatlon of stochastlc genes by proceedlng In the followlng way: The pla~nid DNA derlved from the culture of 107 Independent transformants obtalned by one of the two last procedures descrlbed above, Is Isolated. After thls DNA
Is purlfled, It Is partlally dlgested by the Cla I restrlctlon enzyme (procedure 11) or by the Pst I restrlctlon enzyme (procedure 111). After Inactlvation of the enzyme, the partlally dlgested DNA Is treated wlth T4 DNA llgase, whlch has the effect of creatlng a very large number of new sequences, whlle conservlng 13~3337 , 1 the fundamental properties of the initial sequences. This new ensemble of stochastic sequences can then be used to transform competent cells.
In addition, the stochastic genes cloned by procedures 11 and 111 can be excised intact from the pUC8 expression vector by utilizing restrictlon sTtes belonging to the cloning vector and not represented in the stochastic DNA sequences.
Recombination within the stochastic genes generated by the two procedures just descrtbed, which results from the internal homology due to the recurrent molecular motifs, is an important additional method to achieve in vivo mutagenesis of the coding sequences. This results in an augmentation of the number of new genes which can be examined.
Finally, for all the procedures to generate novel synthetic genes, Tt is possible to use a number of common technlques to modify genes In vivo or in vitro, such as a change of reading frame, inversion of sequences wtth respect to their promoter, point mutations, or utilization of host cells expressing one or several suppressor tRNAs.
In considering the above description, it is clear that it is possible to construct, in vitro, an extremely larse number ( for example greater than a billlon) different genes, by enzymatic polymerization of nucleotTdes or of oligonucleotides. This polymerization is carried out in a stochastic manner, as determined by the respective concentrations of the nucleotides or oligonucleotides present in the reaction mixture.
As indlcated above, two methods can be utilized to clone such genes ~or coding sequences): the polymerlzation can be carried out dtrectly on a cloning expression vector, whTch was previously linearized; or it is possible to proceed sequentlally to the polymerization then the ligation of the polymers to the expression vector.
In the two cases, the next step is transformation or transfection of competent bacterial cells (or cells in culture) . This step constitutes cloning the stochastic genes in living cells where they are indefinitely propagated and expressed.
Clearly, In additlon to the procedures which were described above, it Is feasible to use all other methods which are appro priate for the synth esis of stochastlc sequences. In partlcular, it is posslble to carry out polymeriza tion, by biochemlcal means, of slngle stranded oligomers of DNA or RNA obtained by chemical synthesis, then treat these segments of i~NA or RNA by established procedures to generate double stranded DNA (cDNA) In order to clone such genes.

Screening or selectlon of clones of transformed host cells The final step of the procedure accordlng to the Invention ~ 3~9g37 conslsts in examlning the transformed or transfected cells by selection or screenlng, in order to Isolate one or several cells whose transforming or transfecting DNA leads to the synthests of a transcription product ti~iA) or translation product (protein) having a deslred property. These properties can be, for example, enzymatic, functlonal, or structural.
One of the most important aspects of the procedure, according to the inventton, is that it permits the simultaneous screening or selection of an exploitable product ~i~ A or protein) and the gene which produces that product. In addition, the DNA synthesized and cloned as descrTbed, can be selected or screened in order to tsolate sequences of DNA constituting products in themselves, havTng exploitable biochemical properties.
~le shall now describe, as non-limitating examples, preferred procedures for screening or selection of clones of transformed cells such that the novel proteins are of interest from the point of view of industrial or medtcal applications.
One of these procedures rests on the idea of producing, or obtaTning, polyclonal or monoclonal antibodies, by established techniques, dtrected against a protetn or another type of molecule of biochemical or medical interest, where that molecule is, or has been rendered, immunogenic, and thereafter using these ant~bodies as probes to identify among the very large number of clones transformed by stochastic genes, those whose protein react with these antibodies. rhis reaction is a re-sult of a structural (epitope) homology which extsts between the polypeptide synthesized by the stochastic gene and the initial molecule It is possible in this way to isolate numbers of novel proteins wtth molecular features slmilar to the epitopes or antigenic determinants on the initial molecule. Such novel proteins are candidates to simulate, stimulate, modulate, or block the effect of the initial molecule. It should be clear that this means of selection or ~creening can have very many pharmacologic and biomedical applicattons. As noted above, the peptides identified as havlng epitopes similar to the tnitial molecule of 1nterest can be improved by modifylng the stochastlc genes coding for the satd identifTed proteins or peptides, followed by recloning and rescreening, or derlvltization of those peptides themselves by known procedures.

Below we descrlbe, as a non llmlttng example, thls first mode of operation In a concrete case:
EGF, ~epidermal growth factor) is a small protein present In the blood, whose role Is to stTmulate the growth of eplthellal cells.
Thls effect ts obtained by the interaction of EGF wlth a speciflc receptor sttuated in the membrane of epithellal cells. Prepare antlbodles dlrected agalnst EGF by Injectlng animals wlth EGF
coupled to KLH (keyhole llmpet hemocyanln) to augment the Immunogeneclty of the EGF. The anti-EGF antibodies of the Immunlzed anlmals are purlfled, for example, by passage over an affInl ty column, where the llgand Is EGF or a synthetlc peptlde 1~3~337 corresponding to a fragment of EGF. The purified anti-EGF
antibodies are then used as probes to screen a large number of bacterial clones Iysed by chloroform and on a solid support. The antl-EGF antibodles bind those stochastic peptides or prote7ns whose epitopes resemble those of the initial antigen. The clones contaTning such peptides or proteins are shcwn by autoradiography after incubation of the solid support with radioactive protein A, or after Incubation with a radioactive anti-antlbody antibody.
These steps identify those clones, each of which contains one proteln (and its gene) reacting with the screening antibody. It is feasible to screen among a very large number of colonies of bacterial cells or viral plaques (for example, on the order of 1,000,000) and it is feasible to detect extremely small quantities, on the order of 1 nanogram, of protein product.
Thereafter, the identlfied clones are culturedand the proteins so detected are purified in conventional ways. These proteins are tested in vitro In cultures of epithelial cells to determine if they inhibit, simulate, or modulate the effects of EGF on these cultures. Among the proteins so obtained, some may be utilized for the chemo~rapeutic treatment of epttheliomes. The activities of the proteins thus obtained can be improved by mutation of the DNA codlng for the proteins, in ways analogous to those described above, or by dertvitizing the proteins identtfied.
A variant of this procedure consists in purifying these stochastic peptides, polypeptldes or proteins, which have epitopes or molecular features causing them to be bound by anttbodtes against some anttgens, for example anttgens of a pathogen, and then utllizing the identtfied peptides as vaccines or more generally uttlizing them to confer an immun ity against a pathogenic agent or to exerciSe other effects on the immunologlcal system, for example, to create a tolerance or dimintsh hypersensitivity with respect to a gtven anttgen, in particular due to blndlng of these pepttdes, polypeptldes or protetns with the antibodies directed against this antigen. It is clear that it is possible to use such peptldes, polypeptldes or proteins In vitro as well as in vivo.
More precisely, in the ensemble of novel proteins which react with the antibodies agatnst a given antigen X, each has at least one epttope in co~mon with X, thus the ensemble has an ensemble of epttopes in common with X. This permlts utllization of the ensemble or sub-ensemble as a vaccine to confer immunity against X. It is, for example, easy to purlfy one or several of the capsid proteins of the hepatTtis B virus. These proteins can then be injected tnto an antmal, for example, a rabbit, and the anttbodtes correspondlng to the inttlal antlgen can be recovered by affinity column purlflcation. These antlbodles may be used, as descrlbed above, to Identlfy clones producing at least one proteln having an epitope resemblIng at least one of the epltopes of the Initlal antlgen. Atter purlftcatton, these protetns are used as anttgens (either alone or In combination) wtth the aim of conferlng protectlon against hepatltls B. The flnal productlon of the vaccine does not require further access to the Inltlal pathogentc agent. Nor Is It required that the Initlal antigens derlved from the hepatltls i3 vlrus be protetn antlgens, rather ~ ~39i~3~

they mtght include polysaccharide or other antigenic determinants.
Further, in favorable cases, no access to the initial pathogen is needed, rather the high titre circulating antibodies against the pathogen derlved from an animal or human exposed to the pathogen can be used as the initial step to screen for peptides bound by those high titre antibodies. Such high titre circulating antibodies can reach 1~ to 10~ of all circulating antibodies, hence 1~ - 10% of the stochasttc peptides or polypeptides identified as crossreacting will have antigenic determinants similar to the (perhaps unknown) pathogen. This mixture of identified cross reacting peptides can be used as a vaccine. Or the subset of peptides cross reactins with the high titre antibody molecules can be selected by screening the set of cross reacting peptides with the serum, and tdentifying those peptides to which a hlgh level of circulating antibody is present in the serum. This selected set of cross reactino peptldes may then be used with the aim of producing a vaccine confering immunity, or as agents with other immuno-modifying actions.

Note that, durlng the description of the procedures above, a number of means to achieve selection or screening have been described. All these procedures may require the purification of a partlcular proteln from a transformed clone. These protein purTfications can be carrTed out by established procedures and utilize, in particular, the techniques of gel chromatography, by ion exchange, and by affinTty chromatography. In addition, the proteins generated by the stochastic genes can have been cloned in the form of hybrld protetns havTng, for example, a sequence of the B - galactosidase enzyme which permits affInity chromatography against anti - B-galactosidase antibodies, and allows the subsequent cleavage of the hybrid part ( that is to say, allowing separation of the novel part and the bacterial part of the hybrid protein.
Below we descrlbe the principles and procedures for selection of peptides or polypeptldes and the corresponding genes, according to a second method of screening or selection based on the detection of the capacity of these peptides or polypeptides to catalyse a specific reaction.
As an concrete and non limiting example, screening or selection in the particular case of proteins capable of catalysing the cleavage of lactose, normally a functlon fulfllled by the enzyme B-galactosidase (i3-gal) wlll be described.
As noted above, the first step of the procedure cons7sts in generatlng a very large ensemble of expresslon vectors, each expressing a dlstlnct novel proteln. To be concrete, for example, choose the pUC8 expresslon vector with clonlng of stochastlc sequences of DNA In the Pst I restrlctlon slte. The plasmids thus obtalned are then Introduced In a clone of E coll from whose genome the natural gene for B-galactosidase, Z,and a second gene EBG , unrelated to the first but able to mutate towards B -gal function, have both been elImlnated. Such host cells (Z-,EBG-) are not able by themselves to hydrolyse lactose, and as a ~3~9~7 consequence to use lactose as a carbon source for growth. This permits utilization of such host clones for screening or selection for B-gal function.
co~enient biologTcal assay to analyse transformed E coli clones for those which have novel genes expressing a B gal functions consists in the culture of bacter7a transformed as described In petri dishes containing X-gal in the medium. In this case, all bacterial colonies expressing a B gal function are visualized as blue colonies. By using such a biological assay, it Is possible to detect even weak catalytic activity. The specific activity of characteristic enzymes ranges from lO and lO,000 product molecules per second.
Supposing that a protein synthesized by a stochastic gene- has a weak specific acitivity, on the order of one molecule per lO0 seconds, i t remalns i~ossible to detect such catalytic activity.
In a petrT dish containlng X-gal in the medium, and in the presence of the non metabolizable inducer IPTG (isopropyl-D-thio galactoside) visulallzatlon of a blue region requires cleavage of about 10l~ to lol molecules of X gal per square millimeter. A
bacterial colony expressing a weak enzyme and occupying a surface area of ln~ has about 107 to lo8 cells. If each cell has only one copy of the weak enzyme, each cell would need to catalyse cleavage of between 10,000 and 100 of X gal to be detected, which would require beween 2.7 and 270 hours. Since under selective conditions it is possible to amplify the number of copies of each plasmid per cell to 5 to 20 copies per cell, or even to lO0 or lO00, and because up to 10% of the protein of the cell can be specified by the new gene, the duration needed to detect a colony blue in the case of lO0 enzyme molecules of weak activity per cell is on the order of 0.27 to 2.7 hours.
As a consequence of these facts, screening a very large number of independent bacterial colonies, each expressing a different novel sene, and using the capacity to express a B gal functton as the selection criterion, is fully feasible. It is posslble to carry out screening of about 2000 colonies in one Petrl dish of lO cm diameter. Thus, about 20 million colonies can be screened on a sheet of X gal agar l square meter.
It is important to note that bacterial colonies which appear blue on X gal Petri dlshes might be false positlves due to a mutation in the bacterial genome which confers on It the capacity to metabotise lactose, or for other reasons than those which result from a catalytic actlvity of the novel protein expressed by the cells of the colony. Such false posltives can be directly eliminated by purifying the DNA of the expression vector from the posltive colony, and retransformin~ Z-, EBG- E coli host cells.
If the B gal actlvity is due to the novel protein coded by the new gene in the expresslon vector, all those cells transformed by that vector wlll exhlblt B gal function. In contrast, tf the initial blue colony Is due to a mutaticn in the genome of the host cell, it is a rare ev-~nt and independent of the transformation, thus the number of cells of the new clone of transformed E coli capable of expressing B gal functlon wlll be small or zero.

The power of mass simultaneous puriflcation of all the expression vectors from all the positive clones tblue) followed by retransformation of naive bacterla should be stressed. Suppose that the aim is to carry out a screening to select proteins having a catalytlc function, and that the probability that a new peptide or polypeptide carries out this function at least weakly ts 10-6 , whlle the probability that a clcne of the E coli bacterial host undergoes a mutation rendering it capable of carrytng out the same function Ts 10-5 , then it can be c21cul ated that among 20 million transformed bacteria which are screened, 20 positive clones will be attributable to the novel genes in expression vectors which each carries, whTle 200 positive clones will be the result of genomic mutation. '~lass purification of the expression vectors from the total of 220 positive bacterial clones followed by retransformation of naive bacteria with the mixture of these expression vectors will produce a large number of positive clones conststing of all those bacteria transformed with the 20 expression vectors which code for the novel proteins having the desired function and a very small number of bacterial clones resulting from genomic mutatlons and containing the 200 expression vectors whlch are not of interest. A small number of cycles of purification of expression vectors from positlve bacterial colonies, followed by such retransformation, allows the detection of very rare expression vectors truely positive for a desired catalytic .activity despite a high background rate of mutations In the host cells for the same function.
Following screening operations of this type, it is possible to purlfy the new protein by established techniques. The production of that protein in large quantity is made possible by the fact that identification of the useful proteln occurs together with simultaneous identTfication of the gene coding for the same protein. Consequently, either the same expression vector can be used, or the novel gene can be transplanted into a more appropriate expression vector for its synthesis and isolation in large quantity.
It Is feasible to apply this method of screening for any enzymatic function for which an appropriate biological assay exists. For such screenings, It is not necessary that the enzymatic function whlch is sought be useful to the host cell. It is possible to carry out screenings not only for enzymatic functions, but for any other deslred property for which tt is possible to establIsh an approprlate blologlcal assay. Further, tt Is feasible to carry out, even In the slmple case of B - gal function vlsualized on an X-gal Petri plate, a screening of on the order of 100 mlllion, or even a blllion novel genes for that catalytic acttvity or other desired property.
Selectlon o~ transformed host cells.
On the other hand, It is posslble to use selectlon technlques for any property, catalytic or otherwlse, where the presence or absence of the property can be rendered essenttal for the survival of the host cells contalning the expression vectors whlch code for the novel genes, or also can be used to select for those vlruses " ~,. ,~

1~39~7 ~' coding and expressing the destred novel gene. As a non-limitlng but concrete example selection for B galastosidase function shall be described. An appropriate clone of Z-EBG- E. coli is not able to grow on lactose as the sole carbon source. Thus after carrylng out the first step described above it is possible to culture a very large number of host cells transformed by the expresslon vectors codfng for the novel genes under selective condltions either progressive dlminution of other sources of carbon or utilization of lactose alone from the start. During the course of such selection in vivo mutagenesis by recombination or by explicitly recoverlng the expression vectors and mutagenizing their novel genes in vitro by vzrious mutagens or by any other common technique permits adaptive improvements in the capacityto fulfil the desired catalytic function. ;Ihen both selection techniques and convenient bioassay techniques exist at the same time as in the present case it is possible to use selection techniques initially to enrich the representation of host bacteria expressina the B - gal function then carry out a screen7ng on Petri-plateson X-gal medium to establlsh efficiently whTch are the positive cells. In the absence of convenient bioassays application of progresslvely stricter selection is the easiest route to purify one or a small number of distinct host cells whose expression vectors code for the proteins catalysing the desired reaction.
It is po5sible to utilize these techniques to find novel protelns having a large variety of structural and functional characteristics beyond the capacity to catalyse a specific reactton. For example it ts possible to carry out a screen or select for novel proteins which bind to cis-regulatory sites on the DNA and thereby block the expression of one of the host cell s functions or block transcription of the DNA stimulate transcription etc.
For example in the case of E. Coll a clone mutant in the repressor of the lactose operon (i-) expres~s B gal function constitutively due to the fact the lactose operator is not repressed. All cells of this type produce blue clones cn Petrl plates containing X-gal medtum. It is possible to transform such host cells with expresston vectors synthesizing novel proteins and carry out a screen on X-gal Petri plates in order to detect those clones whlch are not blue. Among those some represent the case where the new protetn binds to the lactose operator and represses the synthesis ofi B-gal. It Is then feasible to mass isol2te such plasmids retransform i- hosts isolate those clones which do not produce B-gal and thereafter carry out a detailed verification.
As mentioned above thls procedure can be utilized in order to create then tsolate not only explottable proteins but also RNA
and DNA as products In themselves having exploitable properttes.
Thts results from the fact that on one hand the procedure conststs In creatlng stochastlc sequences of DNA whlch may tnteract dlrectly wlth other cellular or biochemTcal constituents and on the other hand these sequences cloned In expression vectors are transcrlbed into RNA whlch are themselves capable of multiple blochemlcal interactlons.

( An example of the use of the procedure to create and select for a DNA whlch is useful in itself.
Thls example Tllustrates selectton for a useful DNA, and the purification and study of the mechanism of actton of regulatory proteins whTch bind to the DNA. Conslder a preparatlon of the oestradiol receptor, a protein obtained by standard techniques. In the presence of oestradiol, a steroid sexual hormone, the receptor changes conformation and binds tightly to certain specific sequences in the genomic DNA, thus affecting the transcriptlon of genes implicated in sexual differentlation and the control of fertility. By incubating a mixture containing oestradTol, its receptor, and a large number of different stochastic DNA sequences inserted in their vectors, followed by flltration of the mixture across a nitro cellulose membrane, one has a direct selection for those stochasttc DNA sequences binding to the oestrogen-receptor complex, where only those DNAs bound to a protein are retained by the membrane. After washing and elution, the -DNA liberated from the membrane is utilized to transform bacteria. After culture of the transformed bacteria, the vectors which they contain are again purified and several cycles of incubation, filtration and transformation are carried out as described above. These procedures allow the isolation of stochastic sequences of DNA having an elevated affinity for the oestradiol-receptor complex. Such sequences are open to numerous diagnostic and pharmacologic applications, in particular, for testtng synthetic estrogens for the control of fertility and treatment of sterility.

Creation and selection of an RNA useful in itself Let there be a large number of stochastic DNA sequences, produced as has been described and cloned in an expression vector. It follows that the RNA transcribed from these sequences in the transformed host cells can be useful products in themselves. As a non limiting example, it is possible to select a stochastic gene coding for a suppreSSor transfer RNA (tRNA) by the following procedure:
A large number (> lo8 ) of stochastic sequences are transformed into competent bacterial hosts carrying a "nonsense" mutation in the arg E. gene. These transformed bacteria are plated on minimal medium wlthout argenine and wlth the selective antibiotlc for that plasmld (amplclllin if the vector is pUC8). Only those transformed bacteria which have become capable of synthesizing arginine will be able to grow. Thls phenotype can result elther from a back mutation of the host genome, or the presence in the cell of a suppressor tRNA. It is easy to test each transformed colony to determlne If the arg+ phenotype Is or Is not due to the presence of the stochastic gene In Its vector; it sufflces to purlfy the plasmid from thls colony and verlfy that it confers an Arg+ phenotype on all arg E cells transformed by It.

Selectlon of proteins capable of catalyslng a sequence of 1 3 3 ~ 7 , ~

reactions.
Below we describe another means of selection, open to independent applIcations, based on the principle of slmultaneous and parallel selection of a certa1n number of novel proteins capable of catalysing a connected sequence of reactions.
The basic idea of this method is the following: given an inltial ensemble of chem7cal compounds considered as building blocks or elements of construction from which it is hoped to synthesize one or several desired chemical compounds by means of a catalysed sequence of chemical reactions, there exists a very large number of reaction routes which can be partially or completely substituted for one another, which are all thermodynamically possible, and which lead from the set of building blccks to the desired target compound(s). Efficient synthesis of the target compound is favored if each step of at least one reaction pathway leading from the building block compounds to the target compound is comprised of reactions each of which is catalysed. On tne other hand, it is relatively less important whlch among the many independent or partially independent reaction pathways is catalysed. In the previous description, we have shown how it is possible to obtain a very large number of host cells each of which expresses a distinct novel protein.
Each of these novel proteins is a candidate to catalyse one or another of the possible reactions,in the set of all the possible reactlons leading from the ensemble of building blocks to the target compound(s). If a sufficiently large number of stochastic proteins is present in a reactton mixture containing the buiIding block compounds, such that a sufficient-ly large number of the possible reactions are catalysed, there is a high probability that one connected sequence of reactions leading from the set of bulIding block compounds to the target compound will be catalysed by a subset of the novel proteins. It Is clear that this procedure can be extended to the catalysis not only of one, but of several target compounds simultaneously.
Based on thls prlnciple it Is posslble to proceed as follows in order to select In parallel a set of novel proteins catalyslng a deslred sequence of chemlcal reactlons:
1. SpecTfy the desired set of compounds constltutlng the buiIding blocks, utillzlng preferentlally a reasonably large number of dlstinct chemlcal species In order to increase the number of potential concurrent reactlons leadlng to the deslred target compound(s).
2. Uslng an approprlate volume of reactlon medium, add a very large number of novel stochastlc proteins isolated from transformed or transfected cells synthesizIng these protetns.
Carry out an assay to determlne If the target compound is formed.
If It Is, conflrm that thls formatlon requlres the presence of the mlxture of novel protelns. If so, then then the mlxture should contaln a subset of prote1ns catalyslng one or several reaction pathways leadlng from the bu11dlng block set to the target 13 ~9~37 compound. Purify and dlvide the initial ensemble of clones which synthesize the set of novel stochastic proteins. Thereafter, retest the subset to see if is able to catalyse the sequence of reactions leading to the target com~)und.

i1Ore precisely, as a non limittng example, below we describe selection of a set of novel proteins capable of catalysing the synthesis of a specific small peptide, In particular, a pentapeptide, starting from a building block set constituted of smaller peptides and amino acids. All peptides are consistuted by a linear sequence of 20 different types of amino acids oriented from the amino to the carboxy terminus. Any peptide can be formed in a single step by the terminal condensation of two smaller peptides (or of two amino acids), or by hydrolysis of a larger pentide. A peptide with M residues can thus be formed by M - l condensation reactions. The number of reactions, R, by which a set of peptides having lengths 1,2,3...M residues can be interconverted is larger than the number possible molecular species, T. This can be expressed as R/T - M - 2. Thus, starting from a glven ensemble of peptTdes, a very large number of independent or partially independent reaction pathways lead to the synthesis of a specific target peptide. Choose a pentapeptide whose presence can be determined conveniently by some common assay technique for example Hi~C (liquid phase high pressure chromatography), paper chromato~iraphy~ etc. Formation of a peptide bond requires energy in a dilute aqueous medium, but if the peptides participating in the condensation reactions are adequately concentrated, formation of peptide bonds is thermodynamically favored over hydrolysis and occurs efficiently in the presence of an appropriate enzymatlc catalyst, for example pepsin or trypsln, wlthout requiring the presence of ATP or other hlgh energy compounds. Such a reaction mTxture of small peptides, whose amino aclds are marked radioactively to act as tracters with 3H, 14C,35S, constituting the buildlng block set can be used at sufficientlyhigh concentrations to lead to condensation reactions.
For example, it is teasip~e to proceed as follcws: 15 mg of each amino acid and small peptides having 2 to 4 amino acids, chosen to constitute the building block set, are dissolved in a volume of 0.25ml per l.0 ml of a O.lM pi~ 7.6 phosphate buffer. A large number of novel protelns, generated and isolated as described above are purifled from theTr bacterlal other host cells. The mixture of novel proteins is dlssolved to a final concentration on the order of 0.8 to 1.0 mg/ml In the same buffer. 0.25 ml to 0.5 ml of the proteln mlxture is added to the mixture of bulIdlng blocks. Thls is incubated at 25~C to 4~C for l to 40 hours.
AlIquots of 8 ul are removed at regular Intervals, the first Is used as a blank and taken before addition of the mlxture of novel proteins. These aliquots are analysed by chromatograPhY
uslng n-butanol-acetic acld-pyrldlne-water (30:6:20:24) as the solve~t. The chromatogram is dried, and analysed by nlnhydrln or autoradlography (with or wlthout IntenslfyIng screens). Because the compounds constituting the bulldlng block set are radlcactlvely marked, the target compound wlll be radioactive and it will have a speclflc actlvlty hlgh enough to permit detectlon 13 39'~-3~

at the level of 1 - 10 ng. In place of standard chromatographlc analysis, It is posstble to use Hi~ C (high pressure liquid chromatography) whlch is faster and simpler to carry out. More generally~all the usual analytic procedures can be employed.
Consequently it Is possible to detect a yield of the target compound(s) of less than one part per million by weight compared to the compounds used as initial buiIding blocks.

If the pentapeptide is formed in the conditions described above, but not when an extract is utilized which is derived from host cells transformed by an expressTon vector contalning no stochastic genes, the formation of the pentapeptide is not the result of bacterial contaminants and thus requires the presence of a subset of the novel proteins in the reaction mixture.
The following step consists in the separation of the particular subset of cells which contain expression vectors with the novel proteins catalysTng the sequence of reactions leading to the target ptntapeptide. As an example, If the number of reactions forming this sequence is 5, there are about 5 novel proteins which catalyse the necessary reactions. If the clone bank of bacteria containing the expression vectors which code for the novel genes has a number of distinct novel genes which is on the order of 1,000,000, all these expression vectors are isolated en masse and retransformed into 100 distinct sets of 1 o8 bacteria at a ratio of vectors to bacteria which is sufficiently low that, on average, the number of bacteria in each set which are transformed is about half the number of initial genes, ie about 500,000.
Thus, the probability that any aiven one of the 100 sets of bacteria contains the entire set of 5 critical novel proteins is (1/2)5 = 1/32. Among the 100 initial sets of bacteria, about 3 will contain the 5 critical transformants. In each of these sets, the total number of new genes is only 500,000 rather than 1,000,000. ~y successive repetitions the total number of which is about 20 in the present case, thls procedure isolates the 5 crltical novel genes. Following this, mutagenesls and selection on this set of 5 stochastic genes allows improvement of the necessary catalytic functlons. In a case where it is necessary to catalyse a sequence of 20 reactions, and 20 genes coding novel proteins need to be isolated in parallel, it suffic es to adjust the multiplicity of transformation such that each set of 109 bacterla receives 80~ of the lOe6 stochastic genes, and to use 200 such sets of bacteria. The ~robability that all 20 novel proteins are found in one set is 0.~ - 0.015. Thus, about 2 among the 200 sets will have the 20 novel genes which are needed to catalyse the formation of the tarset compound. The number of cycles required for isol-~tiGn of the 20 novel genes ts on the order of 30.
The prlnclples and procedures descrTbed above generalIze from the case of peptides to numerous areas of chemistry in which chemical reactlons take place tn aqueous medium, in temperature, p~,and concentration conditions which permlt general enzymatlc function.
In each case it is necessary to make use of an assay method to detect the formatlon of the deslred target compund(s). It Is also ~39937 necessary to chose a sufficTently large number of bullding block compounds to augment the number of reaction sequences which lead to the tareget compound.
The concrete example whtch was given for the synthesis of a target pentapeptlde can also be generalized as follows:
The procedure as described, generates among other products, stochasttc peptides and proteins. These peptides or proteins can act, cataIyt7cally or in other ways, on other compounds. They can equally constitute the substrates on which they act. Thus, it is possible to select (or screen) for the capacity of such stochastic peptides or proteins to interact amons themselves and thereby modify the conformation, the structure or the function of some among them. Simila~ly , it is possible to select (or screen) for the capactty of these peptides and proteins to catalyse among themselves, hydrolytic, condensation, transpeptidation or other reactions modifying the peptides. For example, the hydrolylsis of a give stochastic peptide by at least one member of the set of stochastlc peptides and proteins can be followed and measured by radicactive marking of the given protein followed by an incubation with a mi~u~-eOf the stochastic proteins In the presence of ions such as t~g,Ca,Zn, Fe and ATP or GTP. The app~arance ~f radioactive fragments of the marked protein Is mezsured as described. The stochastic protein(s) which catalyse this reaction can aaain be Tsolated, along with the gene(s) producing them, by sequentlal diminution of the library of transformed clones, as describedabove.
An extension of the procedure consists tn the selection of an ensemble of stochastic pepttdes and polypeptides capable of catalystn~ a set of reactions leading from the inlttal bu71dtng blocks (amtno actds and small peptides) to some of the peptides or polypepttdes of the set. It Is therefore also possible to select an ensemble capable of catalysing its own synthesis; such a reflexively autocatalyttc set can be established in a chemostat where the products of the reactions are constantly dtluted, but where the concentration of the butlding blocks are maintained constant. ~Iternztively, synthesis of such a set is aided by enclosing the complex set of peptides in liposomes by standard techniques. In a hypertonic aqueous environment surroundins such liposomes, condensation reactions formtng larger peptides lowers the osmottc pressure tnstde the Itposomes, drtves water molecules produced by the condensatton reactions out of the liposomes, hence favors synthesis of larger polymers. Extstence of an autocatalytic ensemble can be verifted by two dimenstonal gel electrophorests and by Hi~C, showing the synthesis of a stable distributton of peptides and polypeptides. The approprlate reaction volume depends on the number of molecular spectes used, and the concentrattons necessary to fav~ the formation of peptide bonds over their hydrolysts. The dtstributton of molecularspecies of an autocatalyttc ensemble ts free to vary or change due to the emergence of vartant autocataIyttc ensembles. The pepttdes and polypepttdes whtch constitute an autocataly tic set may have certatn elements in common wtth the large intttal ensemble 1~39~37 (consltituted of coded peptides and polypeptides as glven by our procedure) but can also contaln pepttdes and polypeptides whlch are not coded by the ensemble of stochastic genes codlng for the InTt1al ensemble of peptides and proteins.
The set of stochastic genes whose products are necessary to establish such an autocatalytic set can be Isolated as has been described, by sequential diminution of the library of transformed clones. In addition, an autocatalytic set can contain coded pepti~as initially coded by the stochastic genes and syntheslzed continuously in the autocatalytic set. To isolate this coded subset of peptides and proteins, the autocatalycic set can be used to obtain, through immunization in an animal, polyclonal sera recognizing a very large number of theconstituents of the autocatalytic set.
These sera can be utilized to screen the library of stochastic genes to find those genes expressing proteins able to combine with the antibodies present in the sera.
This set of stochastic genes expresses a large number of coded stochastic proteins which persist in the autocatalytic set. The remainder of the coded constituents of such an autocatalytic set can be isolated by serial diminution of the library of stochastic genes, from which the subset detected by immunological methods has first been subtracted.
Such autocatalytic sets of peptides and proteins, obtained as noted, may find a number of practical applications.

Claims (44)

1. A method of identifying a peptide, polypeptide or protein having a binding property to a ligand, comprising:
(a) providing a ligand for detecting said binding property;
(b) synthesizing a diverse population of stochastically generated polynucleotide sequences, said polynucleotide sequences encoding two or more amino acid residues at four or more amino acid positions;
(c) inserting said diverse population of stochastically generated polynucleotide sequences into a population of expression vectors to form a diverse population of expression vectors containing stochastically generated polynucleotide sequences;
(d) expressing said diverse population of expression vectors containing stochastically generated polynucleotide sequences to produce a diverse population of peptides, polypeptides or proteins containing said two or more amino acid residues at four or more amino acid positions; and (e) screening said diverse population of peptides, polypeptides or proteins with said ligand under conditions which allow binding and detection of one or more peptides, polypeptides or proteins having said predetermined property.
2. The method of claim 1, wherein said two or more amino acid residues further comprises all twenty amino acid residues.
3. The method of claim 1, wherein said diverse population of stochastically generated polynucleotide sequences, encode at least 10,000 different peptides, polypeptides or proteins.
4. The method of claim 1, wherein said inserting further comprises hybridization of complementary ends.
5. The method of claim 1, wherein said inserting further comprises ligation.
6. The method of claim 1, wherein said diverse population of stochastically generated polynucleotide sequences are produced by stochastic copolymerization of double stranded oligonucleotides.
7. The method of claim 1, wherein said diverse population of stochastically generated polynucleotide sequences are produced by copolymerization of the four kinds of nucleotide triphosphates consisting of A, C, G and T.
8. The method of claim 1, wherein said diverse population of stochastically generated polynucleotide sequences are produced by chemical synthesis.
9. The method of claim 1, wherein the expression vector is a plasmid.
10. The method of claim 9, wherein the plasmid is pUC8.
11. The method of claim 1, wherein the expression vector is viral DNA.
12. The method of claim 1, wherein the expression vector is a hybrid of plasmid and viral DNA.
13. The method of claim 1, wherein the expression vector is a phage.
14. The method of claim 1, wherein step (c) further comprises digesting the diverse population of expression vectors with a restriction enzyme absent from the expression vector and reinserting the digested products into said digested population of vectors to form a different population having a greater number of new stochastic polynucleotide sequences.
15. A diverse population of peptides, polypeptides, or proteins encoded by stochastic polynucleotide sequences comprising two or more amino acid residues of four or more amino acid positions.
16. A method of isolating a polynucleotide sequence encoding a peptide, polypeptide or protein having a predetermined binding property to a ligand, comprising:
(a) providing a ligand for detecting said binding property;
(b) synthesizing a diverse population of stochastically generated polynucleotide sequences, said polynucleotide sequences encoding two or more amino acid residues at four or more amino acid positions, (c) inserting said diverse population of stochastically generated polynucleotide sequences into a population of expression vectors to form a diverse population of expression vectors containing stochastically generated polynucleotide sequences;
(d) expressing said diverse population of expression vectors containing stochastically generated polynucleotide sequences to produce a diverse population of peptides, polypeptides or proteins containing said two or more amino acid residues at four or more amino acid positions;
(e) screening said diverse population of peptides, polypeptides or proteins with said ligand under conditions which allow binding and detection of one or more peptides, polypeptides or proteins to said ligand;
and (f) isolating the stochastically generated polynucleotide sequence or sequences which encoding said peptides, polypeptides or proteins having said predetermined binding property to said ligand.
17. The method of claim 16, wherein said two or more amino acid residues further comprises all twenty amino acid residues.
18. The method of claim 16, wherein said diverse population of stochastically generated polynucleotide sequences, encode at least 10,000 different peptides, polypeptides or proteins.
19. The method of claim 16, wherein said inserting further comprises hybridization of complementary ends.
20. The method of claim 16, wherein said inserting further comprises ligation.
21. The method of claim 16, wherein said diverse population of stochastically generated polynucleotide sequences are produced by stochastic copolymerization of double stranded oligonucleotides.
22. The method of claim 16, wherein said diverse population of stochastically generated polynucleotide sequences are produced by copolymerization of the four kinds of nucleotide triphosphates consisting of A, C, G and T.
23. The method of claim 16, wherein step (c) further comprises digesting the diverse population of expression vectors with a restriction enzyme absent from the expression vector and reinserting the digested products into said digested population of vectors to form a different population having a greater number of new stochastic polynucleotide sequences.
24. A diverse population of polynucleotide sequences encoding a diverse population of ligand binding peptides, polypeptides, or proteins having two or more amino acid residues at four or more amino acid positions.
25. A method of isolating a peptide, polypeptide or protein having a binding property, comprising:
(a) providing a ligand for detecting said binding property;
(b) synthesizing a diverse population of stochastically generated polynucleotide sequences, said polynucleotide sequences encoding two or more amino acid residues at four or more amino acid positions;
(c) inserting said diverse population of stochastically generated polynucleotide sequences into a population of expression vectors to form a diverse population of expression vectors containing stochastically generated polynucleotide sequences;
(d) expressing said diverse population of expression vectors containing stochastically generated polynucleotide sequences to produce a diverse population of peptides, polypeptides or proteins containing said two or more amino acid residues at four or more amino acid positions;
(e) screening said diverse population of peptides, polypeptides or proteins with said ligand under conditions which allow binding and detection of one or more peptides, polypeptides or proteins having said predetermined property;
(f) isolating the stochastically generated polynucleotide sequence or sequences encoding said peptides, polypeptides or proteins having said binding property to said ligand; and (g) using genetic information from said isolated stochastically generated polynucleotide sequence to produce said peptide, polypeptide or protein having said binding property.
26. The method of claim 25, wherein said two or more amino acid residues further comprises all twenty amino acid residues.
27. The method of claim 25, which said diverse population of stochastically generated polynucleotide sequences, encode at least 10,000 different peptides, polypeptides or proteins.
28. The method of claim 25, wherein said inserting further comprises hybridization of complementary ends.
29. The method of claim 25, wherein said inserting further comprises ligation.
30. The method of claim 25, wherein said diverse population of stochastically generated polynucleotide sequences are produced by stochastic copolymerization of double stranded oligonucleotides.
31. The method of claim 25, wherein said diverse population of stochastically generated polynucleotide sequences are produced by copolymerization of the four kinds of nucleotide triphosphates consisting of A, C, G and T.
32. The method of claim 25, wherein said diverse population of stochastically generated polynucleotide sequences are produced by chemical synthesis.
33. The method of claim 25, wherein step (c) further comprises digesting the diverse population of expression vectors with a restriction enzyme absent from the expression vector and reinserting the digested products into said digested population of vectors to form a new different population having a greater number of new stochastic polynucleotide sequences.
34. A method of producing a diverse population of stochastically generated polynucleotide sequences encoding a diverse population of ligand binding peptides, polypeptides or proteins, comprising:
(a) synthesizing a diverse population of stochastically generated polynucleotide sequences, said polynucleotide sequences encoding of two or more amino acid residues at four or more amino acid positions; and (b) inserting said diverse population of stochastically generated polynucleotide sequences into a population of vectors to form a diverse population of vectors containing stochastically generated polynucleotide sequences.
35. The method of claim 34, wherein said two or more amino acid residues further comprises all twenty amino acid residues.
36. The method of claim 34, which said diverse population of stochastically generated polynucleotide sequences, encode at least 10,000 different peptides, polypeptides or proteins.
37. The method of claim 34, wherein said inserting further comprises hybridization of complementary ends.
38. The method of claim 34, wherein said inserting further comprises ligation.
39. The method of claim 34, wherein said diverse population of stochastically generated polynucleotide sequences are produced by stochastic copolymerization of double stranded oligonucleotides.
40. The method of claim 34, wherein said diverse population of stochastically generated polynucleotide sequences are produced by copolymerization of the four kinds of nucleotide triphosphates consisting of A, C, G and T.
41. The method of claim 34, wherein said diverse population of stochastically generated polynucleotide sequences are produced by chemical synthesis.
42. The method of claim 34, further comprising introducing said diverse population of vectors containing stochastically generated polynucleotide sequences into host cells.
43. The method of claim 34, wherein step (b) further comprises digesting the diverse population of expression vectors with a restriction enzyme absent from the expression vector and reinserting the digested products into said digested population of vectors to form a new different population having a greater number of new stochastic polynucleotide sequences.
44. A diverse population of vectors comprising stochastically generated polynucleotide sequences encoding a diverse population of ligand binding peptides, polypeptides, or proteins, said polynucleotide sequence encoding two or more amino acid residues at four or more amino acid positions.
CA000504653A 1985-03-30 1986-03-20 Procedure for obtaining dna, rna peptides, polypeptides, or proteins by recombinant dna techniques Expired - Lifetime CA1339937C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH137985 1985-03-30

Publications (1)

Publication Number Publication Date
CA1339937C true CA1339937C (en) 1998-06-30

Family

ID=4209046

Family Applications (2)

Application Number Title Priority Date Filing Date
CA000504653A Expired - Lifetime CA1339937C (en) 1985-03-30 1986-03-20 Procedure for obtaining dna, rna peptides, polypeptides, or proteins by recombinant dna techniques
CA000617095A Active CA1341595C (en) 1985-03-30 1986-03-20 Procedure for obtaining dna, rna, peptides, polypeptides, or proteins byrecombinant dna techniques

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA000617095A Active CA1341595C (en) 1985-03-30 1986-03-20 Procedure for obtaining dna, rna, peptides, polypeptides, or proteins byrecombinant dna techniques

Country Status (14)

Country Link
US (7) US5723323A (en)
EP (3) EP0229046B1 (en)
JP (4) JP2584613B2 (en)
CN (1) CN86102090A (en)
AU (1) AU4434585A (en)
CA (2) CA1339937C (en)
CH (1) CH0229046H1 (en)
DE (7) DE229046T1 (en)
FR (1) FR2579618B1 (en)
GB (1) GB2183661B (en)
HK (1) HK20292A (en)
IN (2) IN165561B (en)
SG (1) SG7992G (en)
WO (1) WO1986005803A1 (en)

Families Citing this family (746)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866363A (en) 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US5824469A (en) * 1986-07-17 1998-10-20 University Of Washington Method for producing novel DNA sequences with biological activity
US20060008806A1 (en) * 1986-07-17 2006-01-12 University Of Washington Method for producing novel DNA sequence with biological activity
US5266684A (en) * 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
EP0494955B1 (en) * 1989-10-05 1998-07-15 Optein, Inc. Cell-free synthesis and isolation of novel genes and polypeptides
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
DE69132902D1 (en) * 1990-02-15 2002-02-21 Univ North Carolina Chapel Hill METHODS FOR IDENTIFYING HETERO-FUNCTIONAL FUSION PROTEINS
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5639595A (en) * 1990-05-01 1997-06-17 Isis Phamaceuticals, Inc. Identification of novel drugs and reagents
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6127119A (en) * 1990-06-11 2000-10-03 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5726017A (en) * 1990-06-11 1998-03-10 Nexstar Pharmaceuticals, Inc. High affinity HIV-1 gag nucleic acid ligands
US5780228A (en) * 1990-06-11 1998-07-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US6030776A (en) * 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US5472841A (en) * 1990-06-11 1995-12-05 Nexstar Pharmaceuticals, Inc. Methods for identifying nucleic acid ligands of human neutrophil elastase
US5731424A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5837834A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5543293A (en) * 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US5654151A (en) * 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5668264A (en) * 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5853984A (en) * 1990-06-11 1998-12-29 Nexstar Pharmaceuticals, Inc. Use of nucleic acid ligands in flow cytometry
US5686592A (en) * 1990-06-11 1997-11-11 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US5731144A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US5637682A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to the tachykinin substance P
US5763566A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US5629155A (en) * 1990-06-11 1997-05-13 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US6001577A (en) * 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5962219A (en) 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US20040132067A1 (en) * 1990-06-11 2004-07-08 Somalogic, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5846713A (en) * 1990-06-11 1998-12-08 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5693502A (en) * 1990-06-11 1997-12-02 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5707796A (en) * 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5750342A (en) * 1990-06-11 1998-05-12 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5723289A (en) * 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US5635615A (en) * 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
US5972599A (en) * 1990-06-11 1999-10-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US5637459A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US6696252B2 (en) 1990-06-11 2004-02-24 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5874218A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US20060084797A1 (en) * 1990-06-11 2006-04-20 Gilead Sciences, Inc. High affinity TGFbeta nucleic acid ligands and inhibitors
US6083696A (en) * 1990-06-11 2000-07-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands exponential enrichment: blended selex
US5648214A (en) * 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US5864026A (en) * 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5527894A (en) * 1990-06-11 1996-06-18 Nexstar Pharmacueticals, Inc. Ligands of HIV-1 tat protein
US6465189B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Systematic evolution of ligands by exponential enrichment: blended selex
US5641629A (en) * 1990-06-11 1997-06-24 Nexstar Pharmacueticals Inc Spectroscopically detectable nucleic acid ligands
US5789163A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Enzyme linked oligonucleotide assays (ELONAS)
US6140490A (en) * 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US5580737A (en) * 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5763173A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5674685A (en) * 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6331394B1 (en) 1991-06-10 2001-12-18 Gilead Sciences, Inc. Nucleic acid ligands to integrins
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US6177557B1 (en) 1990-06-11 2001-01-23 Nexstar Pharmaceuticals, Inc. High affinity ligands of basic fibroblast growth factor and thrombin
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US6569620B1 (en) 1990-06-11 2003-05-27 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US6124449A (en) * 1990-06-11 2000-09-26 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US6261774B1 (en) 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US5869641A (en) * 1990-06-11 1999-02-09 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of CD4
WO1991019813A1 (en) * 1990-06-11 1991-12-26 The University Of Colorado Foundation, Inc. Nucleic acid ligands
US5688935A (en) * 1990-06-11 1997-11-18 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US6346611B1 (en) 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US5837456A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5587468A (en) * 1990-06-11 1996-12-24 University Research Corporation High affinity nucleic acid ligands to HIV integrase
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5874557A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5861254A (en) * 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US5795721A (en) * 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
US5756287A (en) * 1990-06-11 1998-05-26 Nexstar Pharmaceuticals, Inc. High affinity HIV integrase inhibitors
US5705337A (en) * 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5766853A (en) * 1990-06-11 1998-06-16 Nexstar Pharmaceuticals, Inc. Method for identification of high affinity nucleic acid ligands to selectins
US5849890A (en) * 1990-06-11 1998-12-15 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones
US5789157A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5567588A (en) * 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US6001988A (en) * 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5763177A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6759392B1 (en) 1990-06-11 2004-07-06 Gilead Sciences, Inc. High affinity RNA ligands of basic fibroblast growth factor
US5712375A (en) * 1990-06-11 1998-01-27 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6716580B2 (en) 1990-06-11 2004-04-06 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
CA2105300C (en) 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
US6028186A (en) * 1991-06-10 2000-02-22 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US6762290B1 (en) 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
AU2313392A (en) * 1991-08-01 1993-03-02 University Research Corporation Systematic polypeptide evolution by reverse translation
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
PT1696031E (en) * 1991-12-02 2010-06-25 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5656467A (en) * 1992-01-09 1997-08-12 The Trustees Of The University Of Pennsylvania Methods and materials for producing gene libraries
WO1993019170A1 (en) * 1992-03-16 1993-09-30 Jacob Nathaniel Wohlstadter Selection methods
US5869644A (en) * 1992-04-15 1999-02-09 The Johns Hopkins University Synthesis of diverse and useful collections of oligonucleotidies
US5719273A (en) * 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
US5998142A (en) * 1993-09-08 1999-12-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
WO1995010296A1 (en) * 1993-10-12 1995-04-20 Glycomed Incorporated A library of glyco-peptides useful for identification of cell adhesion inhibitors
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
DK0744958T3 (en) 1994-01-31 2003-10-20 Univ Boston Polyclonal antibody libraries
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US20060257890A1 (en) * 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US7153948B2 (en) 1994-04-25 2006-12-26 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
US6048698A (en) * 1994-09-20 2000-04-11 Nexstar Pharmaceuticals, Inc. Parallel SELEX™
JPH10506463A (en) * 1994-09-21 1998-06-23 サイトーゲン コーポレーション Antigen-binding peptide (abtide) from peptide library
US5885577A (en) * 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
US6013443A (en) * 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
WO1996034875A1 (en) * 1995-05-03 1996-11-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US20010053523A1 (en) * 1995-06-02 2001-12-20 M&E Biotech A/S. Method for identification of biologically active peptides and nucleic acids
ES2276405T3 (en) 1995-06-02 2007-06-16 Gilead Sciences, Inc. OLIGONUCLEOTID LIGANDS OF HIGH AFFINITY TO PDGF.
US5723594A (en) * 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US20090118481A1 (en) * 1995-06-07 2009-05-07 Gilead Sciences, Inc. High Affinity Nucleic Acid Ligands To Lectins
US6475806B1 (en) 1995-06-07 2002-11-05 Praecis Pharmaceuticals, Inc. Anchor libraries and identification of peptide binding sequences
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US6183967B1 (en) 1995-06-07 2001-02-06 Nexstar Pharmaceuticals Nucleic acid ligand inhibitors to DNA polymerases
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
ES2321243T3 (en) * 1995-06-07 2009-06-03 Gilead Sciences, Inc. NUCLEIC ACID LIGANDS THAT BIND DNA POLYMERASES AND INHIBIT THEM.
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US20020028443A1 (en) * 1999-09-27 2002-03-07 Jay M. Short Method of dna shuffling with polynucleotides produced by blocking or interrupting a synthesis or amplification process
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US20020164580A1 (en) * 1995-12-07 2002-11-07 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6455247B1 (en) * 1996-01-23 2002-09-24 Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6365344B1 (en) * 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6838238B1 (en) 1996-10-17 2005-01-04 Invitrogen Corporation Morphatides: novel shape and structure libraries
US6426335B1 (en) * 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
JP2001504328A (en) 1996-10-31 2001-04-03 スミスクライン・ビーチャム・コーポレイション Methods for characterizing and selecting RNA target motifs that bind pharmaceutically used compounds
US20070009930A1 (en) * 1996-12-18 2007-01-11 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
IL130635A0 (en) 1997-01-17 2000-06-01 Maxygen Inc Evolution of whole cells and organisms by recursive sequence recombination
CN1238366C (en) 1997-01-21 2006-01-25 综合医院公司 Selection of proteins using RNA-protein fusions
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US8207093B2 (en) * 1997-01-21 2012-06-26 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US5871924A (en) * 1997-01-27 1999-02-16 Nexstar Pharmaceuticals, Inc. Method for the production of ligands capable of facilitating aminoacyl-RNA synthesis
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US6180341B1 (en) 1997-05-01 2001-01-30 Board Of Regents, The Universiry Of Texas System In vitro scanning saturation mutagenesis of proteins
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
US6391547B1 (en) * 1997-09-09 2002-05-21 Center For The Application Of Molecular Biology To International Agriculture Microbial β-glucuronidase genes, gene products and uses thereof
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
EP1030861A4 (en) 1997-10-31 2001-09-05 Maxygen Inc Modification of virus tropism and host range by viral genome shuffling
JP3712255B2 (en) 1997-12-08 2005-11-02 カリフォルニア・インスティチュート・オブ・テクノロジー Methods for generating polynucleotide and polypeptide sequences
US20060057573A1 (en) 2002-02-15 2006-03-16 Somalogic, Inc Methods and reagents for detecting target binding by nucleic acid ligands
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
AU3909199A (en) 1997-12-15 1999-07-05 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US5989823A (en) 1998-09-18 1999-11-23 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US20030219803A1 (en) * 1997-12-15 2003-11-27 Somalogic, Incorporated Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US7390619B1 (en) * 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
FR2782325B1 (en) * 1998-08-12 2002-05-24 Proteus METHOD OF IDENTIFYING POLYNUCLEOTIDE SEQUENCES AND / OR CORRESPONDING PROTEINS FROM A SAMPLE OF NUCLEIC ACIDS
US7157083B2 (en) * 1998-04-17 2007-01-02 Surrogate Pharmaceutical Pathways, Llc Compositions and methods for treating retroviral infections
JP2002513550A (en) 1998-05-01 2002-05-14 マキシジェン, インコーポレイテッド Optimization of pest resistance genes using DNA shuffling
US7153655B2 (en) * 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
IL140918A0 (en) 1998-07-27 2002-02-10 Genentech Inc Improved transformation efficiency in phage display through modification of a coat protein
US6602685B1 (en) 1998-08-17 2003-08-05 Phylos, Inc. Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules
US6773911B1 (en) 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
US20020055626A1 (en) * 2000-06-09 2002-05-09 Turner C. Alexander Novel human seven transmembrane proteins and polynucleotides encoding the same
US6570003B1 (en) * 2001-01-09 2003-05-27 Lexion Genetics Incorporated Human 7TM proteins and polynucleotides encoding the same
AU774306B2 (en) * 1999-01-05 2004-06-24 Trustees Of Boston University Improved nucleic acid cloning
AU2415200A (en) * 1999-01-18 2000-08-01 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US20030054390A1 (en) * 1999-01-19 2003-03-20 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US20030054360A1 (en) * 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
US20070065838A1 (en) * 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US20090130718A1 (en) * 1999-02-04 2009-05-21 Diversa Corporation Gene site saturation mutagenesis
US6329145B1 (en) 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
EP1165775A2 (en) 1999-03-05 2002-01-02 Maxygen, Inc. Recombination of insertion modified nucleic acids
US6703240B1 (en) 1999-04-13 2004-03-09 Maxygar, Inc. Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes
US7332308B1 (en) 1999-05-21 2008-02-19 The Penn State Research Foundation Incrementally truncated nucleic acids and methods of making same
US6280943B1 (en) * 1999-06-17 2001-08-28 Gilead Sciences, Inc. 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands
JP4737903B2 (en) 1999-07-07 2011-08-03 ザイモジェネティクス, インコーポレイテッド Human cytokine receptor
US6387620B1 (en) 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
DE60042021D1 (en) * 1999-07-29 2009-05-28 Gilead Sciences Inc NUCLEAR ACID SURFACES FOR THE HEPATOCYTIC GROWTH FACTOR / DISPERSION FACTOR (HGF / SF) AND ITS C-MET RECEPTOR
US7005260B1 (en) 2000-01-28 2006-02-28 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6171795B1 (en) 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
US6506887B1 (en) 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
US20020049312A1 (en) * 2000-05-23 2002-04-25 Turner C. Alexander Noel human thrombospondin-like proteins and polynucleotides encoding the same
US6797510B1 (en) * 2001-05-24 2004-09-28 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6541252B1 (en) 2000-05-19 2003-04-01 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6579710B2 (en) * 2000-12-12 2003-06-17 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6841377B1 (en) 2001-06-13 2005-01-11 Lexicon Genetics Incorporated Human kinase and polynucleotides encoding the same
US6586230B1 (en) * 2000-10-27 2003-07-01 Lexicon Genetics Incorporated Human kinase and polynucleotides encoding the same
US20080050809A1 (en) * 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
US6759527B2 (en) 2001-03-20 2004-07-06 Lexicon Genetics Incorporated Human kinase and polynucleotides encoding the same
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
JP2003516755A (en) * 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド Shotgun scanning, a combined method for mapping functional protein epitopes
US7022479B2 (en) * 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
JP2003520050A (en) 2000-01-24 2003-07-02 フィロス インク. Sensitive multiplexed diagnostic assays for protein analysis
AU5311701A (en) * 2000-01-26 2001-08-20 Lexicon Genetics Inc Novel human neurexin-like proteins and polynucleotides encoding the same
US20050239061A1 (en) * 2000-03-01 2005-10-27 Marshall William S Identification and use of effectors and allosteric molecules for the alteration of gene expression
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
AU2001289284A1 (en) * 2000-04-04 2001-10-15 Enanta Pharmaceuticals, Inc. Methods for identifying peptide aptamers capable of altering a cell phenotype
ES2531551T3 (en) * 2000-04-17 2015-03-17 Dyax Corp. Methods for building genetic package presentation libraries for members of a diverse peptide family
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US20020037506A1 (en) * 2000-04-18 2002-03-28 Yun Lin Aptamer based two-site binding assay
US6479262B1 (en) 2000-05-16 2002-11-12 Hercules, Incorporated Solid phase enzymatic assembly of polynucleotides
WO2001094583A2 (en) * 2000-06-07 2001-12-13 Lexicon Genetics Incorporated Human transporter proteins and polynucleotides encoding the same
US6465632B1 (en) * 2000-06-09 2002-10-15 Lexicon Genetics Incorporated Human phosphatases and polynucleotides encoding the same
DE60137223D1 (en) 2000-06-28 2009-02-12 Amgen Inc THYMUS-STROMA LYMPHOPOIETIN RECEPTOR MOLECULES AND THEIR USE
US6994963B1 (en) 2000-07-10 2006-02-07 Ambion, Inc. Methods for recombinatorial nucleic acid synthesis
AU2001273432A1 (en) * 2000-07-13 2002-01-30 Invitrogen Corporation Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix
WO2002008408A2 (en) * 2000-07-21 2002-01-31 Trustees Of Boston University Modular vector systems
AU2001280968A1 (en) * 2000-07-31 2002-02-13 Menzel, Rolf Compositions and methods for directed gene assembly
UA81743C2 (en) 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
EP1311278A4 (en) * 2000-08-07 2005-01-05 Sloan Kettering Institutefor C Method and composition for immunization using mixed pools of mutated nucleic acids or peptides
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
JP2004506447A (en) * 2000-08-22 2004-03-04 レキシコン・ジェネティクス・インコーポレーテッド Novel human 7TM protein and polynucleotide encoding the same
AU2001285326A1 (en) * 2000-08-31 2002-03-13 Lexicon Genetics Incorporated Human kinase proteins and polynucleotides encoding the same
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
EP1330544A4 (en) * 2000-09-26 2005-04-06 Univ Duke Rna aptamers and methods for identifying the same
WO2002031745A1 (en) * 2000-10-10 2002-04-18 Genencor International, Inc. Information rich libraries
CA2425605A1 (en) 2000-10-16 2002-04-25 Gilead Sciences, Inc. Nucleic acid ligands to the prostate specific membrane antigen
WO2002070705A2 (en) * 2000-10-27 2002-09-12 Lexicon Genetics Incorporated Human 7tm proteins and polynucleotides encoding them
WO2002036633A2 (en) * 2000-10-30 2002-05-10 Lexicon Genetics Incorporated Human 7tm proteins and polynucleotides encoding the same
AU2002228633A1 (en) * 2000-11-20 2002-06-03 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US20020165149A1 (en) * 2000-12-08 2002-11-07 Kranz David M. Mutated class II major histocompatibility proteins
CA2431007A1 (en) * 2000-12-11 2002-07-18 Lexicon Genetics Incorporated Novel human kinase and polynucleotides encoding the same
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
WO2002061071A2 (en) 2000-12-18 2002-08-08 Dyax Corp. Focused libraries of genetic packages
US6852844B1 (en) 2000-12-20 2005-02-08 Lexicon Genetics Incorporated Human protocadherin proteins and polynucleotides encoding the same
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
AU2002246858A1 (en) * 2000-12-27 2002-08-06 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
JP4061043B2 (en) 2000-12-28 2008-03-12 株式会社ポストゲノム研究所 Method for producing peptide etc. by in vitro transcription / translation system
WO2002059287A2 (en) * 2001-01-23 2002-08-01 Lexicon Genetics Incorporated Novel human kinases and polynucleotides encoding the same
US7582423B2 (en) * 2001-02-02 2009-09-01 Novici Biotech Llc Population of polynucleotide sequence variants
US20040142433A1 (en) * 2001-02-02 2004-07-22 Padgett Hal S. Polynucleotide sequence variants
WO2002079468A2 (en) * 2001-02-02 2002-10-10 Large Scale Biology Corporation A method of increasing complementarity in a heteroduplex polynucleotide
US7838219B2 (en) * 2001-02-02 2010-11-23 Novici Biotech Llc Method of increasing complementarity in a heteroduplex
US20020127587A1 (en) * 2001-02-13 2002-09-12 Domenica Simms Methods and compositions for isolation of biological macromolecules
US20030175685A1 (en) * 2001-02-22 2003-09-18 Praecis Pharmaceuticals Inc. Methods for identifying peptides which modulate a biological process
US6875845B2 (en) 2001-03-02 2005-04-05 Zymogenetics, Inc. Mouse cytokine receptor
US7807408B2 (en) * 2001-03-19 2010-10-05 President & Fellows Of Harvard College Directed evolution of proteins
AU2002257076A1 (en) 2001-03-19 2002-10-03 President And Fellows Of Harvard College Nucleic acid shuffling
JP2004524043A (en) 2001-04-06 2004-08-12 レキシコン・ジェネティクス・インコーポレーテッド Novel human kinase and polynucleotide encoding the kinase
WO2002081671A1 (en) 2001-04-06 2002-10-17 Lexicon Genetics Incorporated Novel human kinase and polynucleotides encoding the same
US6644173B2 (en) * 2001-04-11 2003-11-11 Keuring, Incorporated Beverage filter cartridge holder
AU2002254773B2 (en) * 2001-05-03 2005-12-08 Rensselaer Polytechnic Institute Novel methods of directed evolution
WO2002090517A2 (en) * 2001-05-09 2002-11-14 Lexicon Genetics Incorporated Novel human kinases and polynucleotides encoding the same
US20020193585A1 (en) * 2001-05-25 2002-12-19 Walke D. Wade Novel human transporter proteins and polynucleotides encoding the same
ATE482227T1 (en) * 2001-05-25 2010-10-15 Univ Duke MODULATORS OF PHARMACOLOGICAL AGENTS
CA2448347C (en) 2001-05-29 2010-09-21 Lexicon Genetics Incorporated Novel human hydroxylases and polynucleotides encoding the same
US8740987B2 (en) * 2001-06-04 2014-06-03 Warsaw Orthopedic, Inc. Tissue-derived mesh for orthopedic regeneration
US20030113714A1 (en) * 2001-09-28 2003-06-19 Belcher Angela M. Biological control of nanoparticles
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20050164515A9 (en) * 2001-06-05 2005-07-28 Belcher Angela M. Biological control of nanoparticle nucleation, shape and crystal phase
US20030148380A1 (en) * 2001-06-05 2003-08-07 Belcher Angela M. Molecular recognition of materials
CA2633171C (en) 2001-06-20 2012-11-20 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
DE10131441A1 (en) * 2001-06-29 2003-01-30 Henkel Kgaa A new group of alpha amylases and a method for identifying and obtaining new alpha amylases
US20040204669A1 (en) * 2001-07-05 2004-10-14 Hofmann Gunter A. Apparatus for electroporation mediated delivery for drugs and genes
CA2450236A1 (en) * 2001-07-06 2003-01-16 Genentech, Inc. Phage displayed pdz domain ligands
US6943001B2 (en) * 2001-08-03 2005-09-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
WO2003012126A2 (en) * 2001-08-03 2003-02-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
DE10138753B4 (en) * 2001-08-07 2017-07-20 Henkel Ag & Co. Kgaa Detergents and cleaners with hybrid alpha-amylases
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
DE60238143D1 (en) 2001-09-18 2010-12-09 Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS OF TUMORS
WO2003029456A1 (en) 2001-10-01 2003-04-10 Dyax Corp. Multi-chain eukaryotic display vectors and uses thereof
US20030073104A1 (en) * 2001-10-02 2003-04-17 Belcher Angela M. Nanoscaling ordering of hybrid materials using genetically engineered mesoscale virus
EP1840211A1 (en) 2001-10-31 2007-10-03 Danisco A/S Pyranosone dehydratase from phanerochaete chrysosporium
AU2002346369B2 (en) 2001-11-14 2009-08-27 Eusa Pharma (Uk) Ltd Anti-IL-6 antibodies, compositions, methods and uses
DE60232688D1 (en) * 2001-11-20 2009-07-30 Univ Duke BOUNDARY-BIOMATERIALS
US6768476B2 (en) * 2001-12-05 2004-07-27 Etenna Corporation Capacitively-loaded bent-wire monopole on an artificial magnetic conductor
AU2002359761A1 (en) 2001-12-18 2003-06-30 Invenux, Inc. Antibiotic compounds
WO2003057921A1 (en) * 2001-12-26 2003-07-17 Sloan Kettering Institute For Cancer Research Dna immunization with libraries of minigenes encoding degenerate variants of major histocompatibility class i restricted epitopes
WO2003057160A2 (en) 2002-01-02 2003-07-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003064612A2 (en) * 2002-01-28 2003-08-07 Sloan-Kettering Institute For Cancer Research Identification of mutant antigens with enhanced immunogenicity
US7078211B2 (en) * 2002-02-01 2006-07-18 Large Scale Biology Corporation Nucleic acid molecules encoding endonucleases and methods of use thereof
US20030157495A1 (en) * 2002-02-01 2003-08-21 Padgett Hal S. Nucleic acid molecules encoding CEL I endonuclease and methods of use thereof
US7662924B2 (en) * 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
AU2003217693A1 (en) * 2002-02-22 2003-09-09 Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US20030166010A1 (en) * 2002-02-25 2003-09-04 Affholter Joseph A. Custom ligand design for biomolecular filtration and purification for bioseperation
US20030224404A1 (en) * 2002-02-25 2003-12-04 Manuel Vega High throughput directed evolution of nucleic acids by rational mutagenesis
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
MXPA04010092A (en) 2002-04-16 2004-12-13 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor.
CA2481411C (en) 2002-04-19 2016-06-14 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
ES2285118T5 (en) * 2002-05-17 2012-09-21 Alligator Bioscience Ab A METHOD FOR IN VITRO MOLECULAR DEVELOPMENT OF A PROTEIC FUNCTION.
EP1513879B1 (en) * 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
DE60319259T2 (en) * 2002-06-14 2009-03-05 Dyax Corp., Cambridge Recombination of nucleic acid library members
AU2003247576A1 (en) * 2002-06-18 2003-12-31 Archemix Corp. Aptamer-toxin molecules and methods for using same
AU2003261264B2 (en) 2002-07-25 2008-12-11 Archemix Corp. Regulated aptamer therapeutics
EP1576151A4 (en) 2002-08-06 2006-05-17 Verdia Inc Ap1 amine oxidase variants
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
ES2343518T3 (en) * 2002-09-09 2010-08-03 Hanall Biopharma Co., Ltd. ALFA INTERFERATED POLYPEPTIDES MODIFIED PROTEASAS RESISTANT.
US9303262B2 (en) 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
US20050064508A1 (en) 2003-09-22 2005-03-24 Semzyme Peptide mediated synthesis of metallic and magnetic materials
EP2364996B1 (en) 2002-09-27 2016-11-09 Xencor Inc. Optimized FC variants and methods for their generation
JP3447009B1 (en) * 2002-10-29 2003-09-16 實 平垣 Construct structure and method for producing the same
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
WO2004047742A2 (en) * 2002-11-21 2004-06-10 Archemix Corporation Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
US20050124565A1 (en) * 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20040197804A1 (en) * 2002-12-03 2004-10-07 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
US20050037394A1 (en) * 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
EP1587831A2 (en) * 2002-12-26 2005-10-26 Applied Research Systems ARS Holding N.V. Spliced variants of lgr6
US20050079574A1 (en) * 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
CN104388449A (en) 2003-03-06 2015-03-04 维莱尼姆公司 Amylases, nucleic acids encoding them and methods for making and using them
CA2889013C (en) 2003-03-07 2018-07-17 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
MXPA05010681A (en) 2003-04-04 2005-12-15 Diversa Corp Pectate lyases, nucleic acids encoding them and methods for making and using them.
US20050250106A1 (en) * 2003-04-24 2005-11-10 David Epstein Gene knock-down by intracellular expression of aptamers
US7964714B2 (en) * 2003-05-12 2011-06-21 Potomac Pharmaceuticals Inc. Gene expression suppression agents
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
CN108486086A (en) 2003-07-02 2018-09-04 维莱尼姆公司 Dextranase, encode they nucleic acid and preparation and use their method
EP2277908A3 (en) 2003-07-08 2011-12-14 Genentech, Inc. IL-17A/F heterologous polypeptides, antibodies and therapeutic uses thereof
EP2311994A1 (en) * 2003-08-01 2011-04-20 Life Technologies Corporation Compositions and methods for preparing short RNA molecules and other nucleic acids
CA2534055A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
WO2005021714A2 (en) 2003-08-11 2005-03-10 Diversa Corporation Laccases, nucleic acids encoding them and methods for making and using them
CA2537055A1 (en) * 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
JP2005065575A (en) * 2003-08-22 2005-03-17 Japan Science & Technology Agency Preparation of protein molecular-diversified population by frame shuffling
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
EP1689432B1 (en) 2003-11-17 2009-12-30 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050112585A1 (en) * 2003-11-21 2005-05-26 Dominic Zichi Method for adjusting the quantification range of individual analytes in a multiplexed assay
EP1697741A4 (en) * 2003-12-04 2008-02-13 Xencor Inc Methods of generating variant proteins with increased host string content and compositions thereof
PT3385384T (en) 2004-02-12 2020-06-30 Archemix Llc Aptamer therapeutics useful in the treatment of complement-related disorders
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
CA2557633A1 (en) * 2004-03-05 2005-09-22 Archemix Corp. Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
US7569223B2 (en) * 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20080214489A1 (en) * 2004-04-19 2008-09-04 Anthony Dominic Keefe Aptamer-mediated intracellular delivery of oligonucleotides
AU2005238490B2 (en) * 2004-04-22 2010-11-18 Tobira Therapeutics, Inc. Improved modulators of coagulation factors
US7579450B2 (en) 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
EP1745292A2 (en) 2004-04-28 2007-01-24 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
US20060292554A1 (en) * 2004-05-18 2006-12-28 Genentech, Inc. Major coat protein variants for C-terminal and bi-terminal display
ES2540728T3 (en) 2004-06-16 2015-07-13 Dsm Ip Assets B.V. Method for enzymatic discoloration of pheophytin
WO2006029258A2 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
EP1789096A4 (en) 2004-09-07 2009-07-08 Archemix Corp Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
GB0422052D0 (en) 2004-10-04 2004-11-03 Dansico As Enzymes
GB0423139D0 (en) 2004-10-18 2004-11-17 Danisco Enzymes
EP2314618A3 (en) 2004-11-12 2011-10-19 Xencor Inc. Fc variants with altered binding to FcRn
DK1772465T3 (en) 2005-01-05 2009-05-25 F Star Biotech Forsch & Entw Synthetic immunoglobulin domains with modified binding properties in regions of the molecule that are not complementarity determining regions
PA8660701A1 (en) 2005-02-04 2006-09-22 Pfizer Prod Inc SMALL AGONISTS AND THEIR USES
WO2006086396A2 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
CA2614769A1 (en) 2005-03-10 2006-09-21 Verenium Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
CN101175769A (en) 2005-03-10 2008-05-07 健泰科生物技术公司 Methods and compositions for modulating vascular integrity
BRPI0609140A2 (en) 2005-03-15 2010-02-17 Verenium Corp cellulases, nucleic acids that encode them and methods for their production and use
JO3058B1 (en) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc Anti-IL-6 Antibodies,Compositions,Methods and uses
WO2006124667A2 (en) 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses
US20060271262A1 (en) * 2005-05-24 2006-11-30 Mclain Harry P Iii Wireless agricultural network
WO2008018854A2 (en) * 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
EP1896073B1 (en) 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
EP1907421A4 (en) * 2005-06-30 2012-03-28 Abbott Lab Il-12/p40 binding proteins
SG2014010029A (en) 2005-08-19 2014-08-28 Abbott Lab Dual variable domain immunoglobin and uses thereof
EP2500355A3 (en) 2005-08-19 2012-10-24 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2360248A1 (en) 2005-08-24 2011-08-24 The Rockefeller University Ply-GBS mutant lysins
US7713689B2 (en) 2005-09-15 2010-05-11 Duke University Non-fouling polymeric surface modification and signal amplification method for biomolecular detection
US8906864B2 (en) * 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
ES2577292T3 (en) 2005-11-07 2016-07-14 Genentech, Inc. Binding polypeptides with diversified VH / VL hypervariable sequences and consensus
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
RS53270B2 (en) 2005-11-30 2018-05-31 Abbvie Deutschland Monoclonal antibodies against amyloid beta protein and uses thereof
AU2006319358B2 (en) * 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
RS53685B1 (en) 2005-12-29 2015-04-30 Janssen Biotech Inc. Human anti-il-23 antibodies, compositions, methods and uses
EP2216403A3 (en) 2006-02-02 2010-11-24 Verenium Corporation Esterases and related nucleic acids and methods
WO2007092313A2 (en) * 2006-02-03 2007-08-16 Indiana University Research And Technology Corporation Construction of open reading frame libraries and protein structures
NZ595498A (en) 2006-02-10 2013-05-31 Verenium Corp Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
ES2682284T3 (en) 2006-02-14 2018-09-19 Bp Corporation North America Inc. Xylanases, nucleic acids that encode them and methods to make and use them
CA2645225A1 (en) 2006-03-07 2007-09-13 Verenium Corporation Aldolases, nucleic acids encoding them and methods for making and using them
EP2316962B1 (en) 2006-03-07 2014-07-09 Cargill, Incorporated Aldolases, nucleic acids encoding them and methods for making and using them
HUE026496T2 (en) * 2006-03-08 2016-06-28 Archemix Llc Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
WO2007126455A2 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
WO2007134050A2 (en) * 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
AT503861B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING T-CELL RECEPTORS
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
AT503902B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING IMMUNE LOBULINS
KR101193722B1 (en) 2006-07-24 2013-01-11 바이오렉시스 파마슈티칼 코포레이션 Exendin fusion proteins
EP2444413A1 (en) 2006-08-04 2012-04-25 Verenium Corporation Methods for oil or gas well drilling, washing and/or fracturing
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
MY188368A (en) 2006-09-08 2021-12-06 Abbott Lab Interleukin-13 binding proteins
WO2008032833A1 (en) 2006-09-14 2008-03-20 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
BRPI0716872A2 (en) 2006-09-21 2015-06-16 Verenium Corp Phospholipases, nucleic acids encoding them and methods for their manufacture and use
EP2617819B1 (en) 2006-09-21 2016-04-27 BASF Enzymes LLC Phytases, nucleic acids encoding them and methods for making and using them
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PL3101128T3 (en) 2006-12-21 2019-09-30 Basf Enzymes Llc Amylases and glucoamylases, nucleic acids encoding them and methods for making and using them
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US7964356B2 (en) 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
CA2675366A1 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual tki therapy
NZ610301A (en) 2007-01-30 2015-03-27 Bp Corp North America Inc Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
US8143046B2 (en) 2007-02-07 2012-03-27 Danisco Us Inc., Genencor Division Variant Buttiauxella sp. phytases having altered properties
AU2008218925A1 (en) 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
ES2556380T3 (en) 2007-02-22 2016-01-15 Genentech, Inc. Procedures to detect inflammatory bowel disease
EP2486928A1 (en) * 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
PE20090329A1 (en) * 2007-05-30 2009-03-27 Abbott Lab HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
US20090203766A1 (en) * 2007-06-01 2009-08-13 Archemix Corp. vWF aptamer formulations and methods for use
EP3241842B1 (en) 2007-06-26 2024-01-31 F-star Therapeutics Limited Display of binding agents
DK2489743T3 (en) 2007-07-17 2015-03-02 Somalogic Inc Aptamers with 5- (N-naphthyl) substituted uridines
EP2033971A1 (en) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP) binding domains of proteins of the Repulsive Guidance Molecule (RGM) protein family and functional fragments thereof and their application
WO2009036379A2 (en) * 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
DK2915564T3 (en) 2007-09-28 2021-02-08 Alexion Pharma Inc Antidotes to factor XA inhibitors and methods for their use
CN110577945A (en) 2007-10-03 2019-12-17 维莱尼姆公司 xylanases, nucleic acids encoding them, and methods for making and using them
JP2011502964A (en) 2007-10-23 2011-01-27 ザ レジェンツ オブ ザ ユニバーシティ オブ コロラド Competitive inhibitors of invariant chain expression and / or ectopic CLIP binding
US8663980B2 (en) * 2007-10-26 2014-03-04 Janssen Biotech, Inc. Vectors, host cells, and methods of production and uses
US8906700B2 (en) 2007-11-06 2014-12-09 Ambergen, Inc. Methods and compositions for phototransfer
EP2242843B1 (en) * 2007-12-31 2015-05-27 XOMA Technology Ltd. Methods and materials for targeted mutagenesis
CN104651381A (en) 2008-01-03 2015-05-27 巴斯夫酶有限责任公司 Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
EP2238261B1 (en) 2008-01-03 2013-12-04 Verenium Corporation Isomerases, nucleic acids encoding them and methods for making and using them
US7682809B2 (en) 2008-01-11 2010-03-23 Agilent Technologies, Inc. Direct ATP release sequencing
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
EP2281078B1 (en) * 2008-04-24 2014-10-22 Dyax Corporation Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab Dual variable domain immunoglobulins and uses thereof
DK2281034T3 (en) 2008-04-30 2016-01-25 Dupont Nutrition Biosci Aps A method using alcohol dehydrogenase Pseudoglucanobacter saccharoketogenes
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
ES2579554T3 (en) 2008-05-09 2016-08-12 Abbvie Deutschland Gmbh & Co Kg Antibodies for the recipient of advanced glycation terminal products (RAGE) and uses thereof
CA2725666A1 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
RU2010153580A (en) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION
CN102124030B (en) * 2008-06-20 2015-06-17 国立大学法人冈山大学 Antibody against oxidized ldl/ss2gpi complex and use of the same
EP2303318A2 (en) 2008-06-20 2011-04-06 Wyeth LLC Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
JP5674654B2 (en) * 2008-07-08 2015-02-25 アッヴィ・インコーポレイテッド Prostaglandin E2 double variable domain immunoglobulin and use thereof
CN104829718A (en) 2008-07-08 2015-08-12 艾伯维公司 Prostaglandin E2 binding proteins and uses thereof
US8703416B2 (en) 2008-07-17 2014-04-22 Somalogic, Inc. Method for purification and identification of sperm cells
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
WO2010011315A2 (en) * 2008-07-25 2010-01-28 Viral Genetics, Inc. Proteins for use in diagnosing and treating infection and disease
US9182406B2 (en) * 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
WO2010017598A1 (en) 2008-08-14 2010-02-18 Arana Therapeutics Limited Anti-il-12/il-23 antibodies
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
JP5390621B2 (en) 2008-10-20 2014-01-15 グワンジュ・インスティテュート・オブ・サイエンス・アンド・テクノロジー Bidentate peptide binder
MX2011005953A (en) * 2008-12-04 2011-08-17 Abbott Lab Dual variable domain immunoglobulins and uses thereof.
EP2379720B1 (en) 2009-01-20 2016-08-17 Alona Zilberberg Mir-21 promoter driven targeted cancer therapy
UA102722C2 (en) * 2009-01-29 2013-08-12 Эббви Инк. Il-1 binding proteins
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
US8030026B2 (en) * 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
US8835610B2 (en) 2009-03-05 2014-09-16 Abbvie Inc. IL-17 binding proteins
EP3604510A1 (en) 2009-03-30 2020-02-05 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
GB0908770D0 (en) 2009-04-24 2009-07-01 Danisco Method
MX355638B (en) 2009-05-21 2018-03-26 Verenium Corp Phytases, nucleic acids encoding them and methods for making and using them.
EP2453910B1 (en) 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PE20121647A1 (en) 2009-08-29 2012-12-31 Abbvie Inc THERAPEUTIC BINDING PROTEINS TO DLL4
TW201119673A (en) 2009-09-01 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2773564A1 (en) * 2009-09-14 2011-03-17 Dyax Corp. Libraries of genetic packages comprising novel hc cdr3 designs
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UA109884C2 (en) 2009-10-16 2015-10-26 A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD
UA111708C2 (en) 2009-10-16 2016-06-10 Бандж Ойлз, Інк. METHOD OF OIL REFINING
CA2778442A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
UY32979A (en) * 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
CN102741294A (en) 2009-11-30 2012-10-17 霍夫曼-拉罗奇有限公司 Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID 2)
CA2780069C (en) * 2009-12-08 2018-07-17 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
CA2789629A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
JP5981853B2 (en) 2010-02-18 2016-08-31 ジェネンテック, インコーポレイテッド Neuregulin antagonists and their use in the treatment of cancer
PE20130214A1 (en) 2010-02-23 2013-03-11 Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
JP5778700B2 (en) 2010-02-24 2015-09-16 イミュノジェン, インコーポレイテッド Folate receptor 1 antibody and immunoconjugate and use thereof
SG10201501562VA (en) 2010-03-02 2015-04-29 Abbvie Inc Therapeutic dll4 binding proteins
CA2808233C (en) 2010-03-03 2017-07-11 Somalogic, Inc. Aptamers to 4-1bb and their use in treating diseases and disorders
CA2795043C (en) 2010-03-30 2019-04-23 Janssen Biotech, Inc. Humanized il-25 antibodies
CN104069512A (en) 2010-04-12 2014-10-01 私募蛋白质体公司 Aptamers to beta-NGF and their use in treating beta-NGF mediated diseases and disorders
MX336196B (en) 2010-04-15 2016-01-11 Abbvie Inc Amyloid-beta binding proteins.
MX342239B (en) 2010-05-03 2016-09-21 Genentech Inc * Compositions and methods for the diagnosis and treatment of tumor.
HUE033063T2 (en) 2010-05-14 2017-11-28 Abbvie Inc Il-1 binding proteins
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
GB201011513D0 (en) 2010-07-08 2010-08-25 Danisco Method
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
DK3741883T3 (en) 2010-07-16 2023-02-20 Adimab Llc ANTIBODIES LIBRARIES
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012051055A2 (en) 2010-10-06 2012-04-19 Bp Corporation North America Inc. Variant cbh i polypeptides
RU2627171C2 (en) 2010-12-21 2017-08-03 Эббви Инк. Il-1 alpha and beta bispecific immunoglobulins with double variable domains and their application
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
DK2658970T3 (en) 2010-12-31 2017-01-16 Bioatla Llc Express humanization of antibodies
AU2012230899A1 (en) 2011-03-21 2013-10-10 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
US9034322B2 (en) 2011-04-21 2015-05-19 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
MX2014000531A (en) 2011-07-13 2014-12-05 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies.
WO2013016449A2 (en) 2011-07-26 2013-01-31 Indicator Systems International, Inc. Assays for the detection of microbes
BR112014005720A2 (en) 2011-09-15 2017-12-12 Genentech Inc method of selecting and / or identifying a usp1 antagonist, uaf1 antagonist and / or an id antagonist that promotes a change in the cellular fate of said method
EP2764093B1 (en) 2011-10-05 2018-04-18 The Rockefeller University Dimeric bacteriophage lysins
RU2014119426A (en) 2011-10-15 2015-11-20 Дженентек, Инк. WAYS OF APPLICATION OF SCD1 ANTAGONISTS
AR088513A1 (en) 2011-10-24 2014-06-18 Abbvie Inc IMMUNO LINKERS AGAINST SCLEROSTINE
JP6180425B2 (en) 2011-11-23 2017-08-23 メディミューン,エルエルシー Binding molecules specific for HER3 and their use
CA2855570A1 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
US10118958B2 (en) 2011-12-14 2018-11-06 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
BR112014015851A2 (en) 2011-12-30 2019-09-24 Abbvie Inc double specific binding proteins directed against il-13 and / or il-17
WO2013109856A2 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
PT2804878T (en) 2012-01-20 2018-11-29 Genzyme Corp Anti-cxcr3 antibodies
ES2676725T3 (en) 2012-01-27 2018-07-24 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of diseases associated with the degeneration of neurites
EP2812350B1 (en) 2012-02-11 2019-04-03 F.Hoffmann-La Roche Ag R-spondin translocations and methods using the same
US20140170159A9 (en) 2012-03-08 2014-06-19 Ge Wei Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
EP3626254A1 (en) 2012-03-16 2020-03-25 University Health Network Soluble toso protein and its use in treating autoimmune disorders
WO2013137920A1 (en) 2012-03-16 2013-09-19 Genentech, Inc. Engineered conformationally-stabilized proteins
CN104168898A (en) 2012-03-16 2014-11-26 霍夫曼-拉罗奇有限公司 Methods of treating melanoma with pak1 inhibitors
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP2841951B1 (en) 2012-04-25 2019-12-11 Biodesy, Inc. Methods for detecting allosteric modulators of proteins
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
SG11201408330XA (en) 2012-05-24 2015-01-29 Mountgate Group Ltd Compositions and methods related to prevention and treatment of rabies infection
JP6629069B2 (en) 2012-06-06 2020-01-15 ゾエティス・エルエルシー Canine anti-NGF antibody and method thereof
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
CA3137438A1 (en) 2012-08-31 2014-03-06 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
SG11201503412RA (en) 2012-11-01 2015-05-28 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
KR20150118159A (en) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 Methods of treating cancer and preventing drug resistance
US9925240B2 (en) 2013-03-06 2018-03-27 Genentech, Inc. Methods of treating and preventing cancer drug resistance
GB201308828D0 (en) 2013-03-12 2013-07-03 Verenium Corp Phytase
BR112015023239A8 (en) 2013-03-14 2018-04-17 Abbott Lab hcv antibody-antigen combination assay and methods and compositions for use thereof
GB201308843D0 (en) 2013-03-14 2013-07-03 Verenium Corp Phytase formulation
MX2015012824A (en) 2013-03-14 2016-06-24 Abbott Lab Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection.
MX2015011606A (en) 2013-03-14 2016-05-17 Genentech Inc Methods of treating cancer and preventing cancer drug resistance.
JP6739329B2 (en) 2013-03-14 2020-08-12 アボット・ラボラトリーズAbbott Laboratories HCV core lipid binding domain monoclonal antibody
CN105324396A (en) 2013-03-15 2016-02-10 艾伯维公司 Dual specific binding proteins directed against il-1 beta and il-17
MX2015011899A (en) 2013-03-15 2016-05-05 Genentech Inc Methods of treating cancer and preventing cancer drug resistance.
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
AU2014235453A1 (en) 2013-03-15 2015-10-08 Genentech, Inc. Biomarkers and methods of treating PD-1 and PD-L1 related conditions
WO2014150914A2 (en) 2013-03-15 2014-09-25 Pioneer Hi-Bred International, Inc. Phi-4 polypeptides and methods for their use
JP6581572B2 (en) 2013-06-07 2019-09-25 デューク ユニバーシティ Complement factor H inhibitor
CA2919437A1 (en) 2013-07-25 2015-01-29 Basf Enzymes Llc Phytase
US10006045B2 (en) 2013-08-16 2018-06-26 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
IL293871A (en) 2013-08-30 2022-08-01 Immunogen Inc Antibodies and assays for detection of folate receptor 1
SG11201601770YA (en) 2013-09-12 2016-04-28 Halozyme Inc Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
CN105705007A (en) 2013-09-13 2016-06-22 先锋国际良种公司 Insecticidal proteins and methods for their use
CA2935378C (en) 2013-12-24 2023-04-18 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
RU2021113662A (en) 2014-02-07 2021-05-31 Пайонир Хай-Бред Интернэшнл, Инк. INSECTICIDE PROTEINS AND METHODS OF THEIR APPLICATION
EP3102684B1 (en) 2014-02-07 2020-05-06 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
CA2941693A1 (en) 2014-03-07 2015-09-11 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
RS60795B1 (en) 2014-04-08 2020-10-30 Boston Pharmaceuticals Inc Binding molecules specific for il-21 and uses thereof
BR112016022910A2 (en) 2014-04-11 2017-10-17 Medimmune Llc bispecific her2 antibodies
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
CA3225091A1 (en) 2014-05-05 2015-11-12 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
RU2016144405A (en) 2014-05-23 2018-06-26 Дженентек, Инк. MiT BIOMARKERS AND WAYS OF THEIR APPLICATION
CN107073121A (en) 2014-06-13 2017-08-18 基因泰克公司 Treatment and the method for prevention cancer drug resistance
CN114057857A (en) 2014-06-20 2022-02-18 豪夫迈·罗氏有限公司 CHAGASIN-based scaffold compositions, methods and uses
CN107108705B (en) 2014-10-16 2021-05-25 先锋国际良种公司 Insecticidal proteins and methods of use thereof
US20170306360A1 (en) 2014-10-24 2017-10-26 Danisco Us Inc. Method for producing alcohol by use of a tripeptidyl peptidase
CA2965438A1 (en) 2014-10-24 2016-04-28 Dupont Nutrition Biosciences Aps Use of proline tolerant tripeptidyl peptidases in feed additive compositions
MX2017005976A (en) 2014-11-10 2017-06-29 Medimmune Ltd Binding molecules specific for cd73 and uses thereof.
EP3789403A1 (en) 2014-11-11 2021-03-10 MedImmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
WO2016106286A1 (en) 2014-12-23 2016-06-30 Biodesy, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
CN107530423B (en) 2015-01-14 2022-04-05 布里格姆及妇女医院股份有限公司 Treatment of cancer with anti-LAP monoclonal antibodies
CA2977026A1 (en) 2015-03-11 2016-09-15 E.I. Du Pont De Nemours And Company Insecticidal combinations of pip-72 and methods of use
CN116063543A (en) 2015-04-24 2023-05-05 豪夫迈·罗氏有限公司 Multispecific antigen-binding proteins
CN108064233B (en) 2015-05-19 2022-07-15 先锋国际良种公司 Insecticidal proteins and methods of use thereof
PE20180193A1 (en) 2015-05-29 2018-01-26 Abbvie Inc ANTI-CD40 ANTIBODIES AND THEIR USES
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
CN107922497B (en) 2015-06-24 2022-04-12 詹森药业有限公司 anti-VISTA antibodies and fragments
BR112017028035A2 (en) 2015-06-26 2018-08-28 Dupont Nutrition Biosci Aps aminopeptidases for protein hydrolysates
JP7203497B2 (en) 2015-06-29 2023-01-13 イミュノジェン・インコーポレーテッド Anti-CD123 Antibodies, and Conjugates and Derivatives Thereof
WO2017011275A1 (en) 2015-07-10 2017-01-19 Nersissian Aram M Factor viii protein compositions and methods of treating hemophilia a
CA2993009A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
CN109475096B (en) 2015-08-06 2022-08-23 先锋国际良种公司 Plant-derived insecticidal proteins and methods of use thereof
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
TWI726936B (en) 2015-11-10 2021-05-11 美商麥迪紐有限責任公司 Binding molecules specific for asct2 and uses thereof
EP3390431A1 (en) 2015-12-18 2018-10-24 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
CA3048204A1 (en) 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response
TWI756204B (en) 2016-02-12 2022-03-01 比利時商楊森製藥公司 Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2017147060A1 (en) 2016-02-25 2017-08-31 Dupont Nutrition Biosciences Aps Method for producing a protein hydrolysate employing an aspergillus fumigatus tripeptidyl peptidase
JP6987072B2 (en) 2016-03-10 2021-12-22 アクセレロン ファーマ インコーポレーテッド Activin type 2 receptor binding protein and its use
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
WO2017172771A2 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
CA3021334C (en) 2016-04-27 2022-11-29 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
CA3018384A1 (en) 2016-05-04 2017-11-09 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
MA51586A (en) 2016-06-02 2019-04-10 Abbvie Inc GLUCOCORTICOID RECEPTOR AND IMMUNOCONJUGATE AGONIST
CN109963870B (en) 2016-06-08 2023-07-28 艾伯维公司 anti-B7-H3 antibodies and antibody drug conjugates
JP2019521973A (en) 2016-06-08 2019-08-08 アッヴィ・インコーポレイテッド Anti-BH7-H3 antibody and antibody drug conjugate
JP2019526529A (en) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド Anti-B7-H3 antibody and antibody drug conjugate
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
EP3472186A1 (en) 2016-06-17 2019-04-24 National Hellenic Research Foundation Systems for recombinant protein production
WO2018005411A1 (en) 2016-07-01 2018-01-04 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
JP2019534858A (en) 2016-09-09 2019-12-05 ジェネンテック, インコーポレイテッド Selective peptide inhibitor of FRIZZLED
CA3037961A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
MX2019003473A (en) 2016-10-03 2019-10-15 Abbott Lab Improved methods of assessing uch-l1 status in patient samples.
EP3535285B1 (en) 2016-11-01 2022-04-06 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
KR20190078648A (en) 2016-11-16 2019-07-04 얀센 바이오테크 인코포레이티드 Methods for treating psoriasis with anti-IL23 specific antibodies
AU2017363309A1 (en) 2016-11-23 2019-07-11 Bioverativ Therapeutics Inc. Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
EP3544628A4 (en) 2016-11-23 2020-11-18 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
CN110088123B (en) 2016-12-14 2023-10-20 先锋国际良种公司 Insecticidal proteins and methods of use thereof
MX2019007491A (en) 2016-12-22 2019-09-06 Pioneer Hi Bred Int Insecticidal proteins and methods for their use.
CA3049105A1 (en) 2017-01-04 2018-07-12 Lauren O. Bakaletz Dnabii vaccines and antibodies with enhanced activity
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
AU2018206560A1 (en) 2017-01-04 2019-07-18 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
WO2018127791A2 (en) 2017-01-06 2018-07-12 Biosion, Inc. Erbb2 antibodies and uses therefore
EP3573658A4 (en) 2017-01-30 2021-07-21 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
JP2020506947A (en) 2017-02-07 2020-03-05 ヤンセン バイオテツク,インコーポレーテツド Anti-TNF antibodies, compositions and methods for treating active ankylosing spondylitis
WO2018148001A1 (en) 2017-02-08 2018-08-16 Pioneer Hi-Bred International Inc Insecticidal combinations of plant derived insecticidal proteins and methods for their use
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
KR102602199B1 (en) 2017-02-27 2023-11-15 리제너론 파아마슈티컬스, 인크. Humanized Models of Kidney and Liver Disorders
AU2018236271B2 (en) 2017-03-15 2023-12-21 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CA3052513A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
JP7344797B2 (en) 2017-04-15 2023-09-14 アボット・ラボラトリーズ Methods to aid in hyperacute diagnosis and determination of traumatic brain injury in human subjects using early biomarkers
EP3624820A1 (en) 2017-04-21 2020-03-25 H. Hoffnabb-La Roche Ag Use of klk5 antagonists for treatment of a disease
EP4230649A3 (en) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
CN110603449A (en) 2017-04-28 2019-12-20 雅培实验室 Method for determining traumatic brain injury using early biomarkers from at least two samples of the same human subject for aiding hyperacute diagnosis
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
BR112019023628A2 (en) 2017-05-11 2020-06-02 Pioneer Hi-Bred International, Inc. RECOMBINANT INSECTICIDE POLYPEPIDE, CHEMICAL INSECTICIDE PROTEIN, FUSION PROTEIN, AGRICULTURAL COMPOSITION, RECOMBINANT POLYNUCLEOTIDE, DNA BUILDING, TRANSGENIC PLANT, METHOD OF INHIBITING THE AGGREGATION OR EXERCISING AGAINST EXERCISE OR EXERCISE , METHOD TO CONTROL PEST INFESTATION AND METHOD TO IMPROVE THE PERFORMANCE OF A CULTURE
CN110651190A (en) 2017-05-25 2020-01-03 雅培实验室 Method for using early biomarkers to help determine whether to perform imaging on a human subject who has suffered or may have suffered a head injury
AU2018275235A1 (en) 2017-05-30 2019-10-31 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers
EP3641752A4 (en) 2017-06-22 2021-03-17 Moonshot Pharma LLC Methods for treating cancer with compositions comprising amlexanox and immune modulators
EP3649474A1 (en) 2017-07-03 2020-05-13 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
CN111094334A (en) 2017-07-19 2020-05-01 美国卫生与公众服务部 Antibodies and methods for diagnosis and treatment of hepatitis B virus infection
CN117050176A (en) 2017-07-31 2023-11-14 豪夫迈·罗氏有限公司 Humanization method based on three-dimensional structure
TW201922780A (en) 2017-09-25 2019-06-16 美商健生生物科技公司 Safe and effective method of treating Lupus with anti-IL12/IL23 antibody
EP3692370A2 (en) 2017-10-04 2020-08-12 OPKO Pharmaceuticals, LLC Articles and methods directed to personalized therapy of cancer
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
JP2021502125A (en) 2017-11-09 2021-01-28 ピンテオン セラピューティクス インコーポレイテッド Methods and Compositions for the Preparation and Use of Humanized Conformation-Specific Phosphorylated Tau Antibodies
WO2019113525A2 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
WO2019112860A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
US20190211098A1 (en) 2017-12-22 2019-07-11 Genentech, Inc. Use of pilra binding agents for treatment of a disease
BR112020010430A2 (en) 2017-12-29 2020-11-24 Abbott Laboratories biomarkers and innovative methods to diagnose and evaluate traumatic brain injury
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
CN111989117A (en) 2018-02-14 2020-11-24 维埃拉生物股份有限公司 Antibodies to the ligand of the mcdonald cat sarcoma (FMS) -like tyrosine kinase 3 receptor (FLT3L) and their use for the treatment of autoimmune and inflammatory diseases
KR20200129125A (en) 2018-03-05 2020-11-17 얀센 바이오테크 인코포레이티드 How to treat Crohn's disease with anti-IL23 specific antibodies
WO2019177690A1 (en) 2018-03-12 2019-09-19 Zoetis Services Llc Anti-ngf antibodies and methods thereof
WO2019213619A1 (en) 2018-05-04 2019-11-07 Abbott Laboratories Hbv diagnostic, prognostic, and therapeutic methods and products
EP3794116A2 (en) 2018-05-17 2021-03-24 BP Corporation North America Inc. Production of 2-keto-3-deoxy-d-gluconic acid in filamentous fungi
TW202016144A (en) 2018-06-21 2020-05-01 日商第一三共股份有限公司 Compositions including cd3 antigen binding fragments and uses thereof
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
WO2020041360A1 (en) 2018-08-21 2020-02-27 Quidel Corporation Dbpa antibodies and uses thereof
CN112969792A (en) 2018-09-07 2021-06-15 巴斯夫植物科学有限公司 Improved methods for producing high levels of PUFAs in plants
CN113412332A (en) 2018-09-07 2021-09-17 巴斯夫植物科学有限公司 Improved methods for producing high levels of PUFAs in plants
CA3110656A1 (en) 2018-09-07 2020-03-12 Basf Plant Science Company Gmbh Improved method for the production of high levels of pufa in plants
SI3883606T1 (en) 2018-09-24 2023-10-30 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
CA3114925A1 (en) 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Compositions and methods for enzymatic disruption of bacterial biofilms
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
US11548941B2 (en) 2018-11-20 2023-01-10 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
EP3883961A1 (en) 2018-11-20 2021-09-29 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
EP3897722A4 (en) 2018-12-18 2022-09-14 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
US20220090125A1 (en) 2018-12-21 2022-03-24 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
EP3911676A1 (en) 2019-01-15 2021-11-24 Janssen Biotech, Inc. Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
KR20210118878A (en) 2019-01-23 2021-10-01 얀센 바이오테크 인코포레이티드 Anti-TNF antibody composition for use in a method of treating psoriatic arthritis
MA55283A (en) 2019-03-14 2022-01-19 Janssen Biotech Inc METHODS FOR PRODUCING ANTI-TNF ANTIBODY COMPOSITIONS
KR20210141998A (en) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 Method of making anti-TNF antibody composition
MA55282A (en) 2019-03-14 2022-01-19 Janssen Biotech Inc MANUFACTURING METHODS FOR THE PRODUCTION OF ANTI-TNF ANTIBODY COMPOSITIONS
JP2022525145A (en) 2019-03-14 2022-05-11 ヤンセン バイオテツク,インコーポレーテツド A production method for producing an anti-IL12 / IL23 antibody composition.
EA202192459A1 (en) 2019-03-18 2021-11-25 Янссен Байотек, Инк. METHOD FOR TREATMENT OF PSORIASIS WITH ANTIBODY TO IL12 / IL23 IN CHILDREN
WO2020227554A1 (en) 2019-05-09 2020-11-12 Genentech, Inc. Methods of making antibodies
KR20220012883A (en) 2019-05-23 2022-02-04 얀센 바이오테크 인코포레이티드 A method of treating inflammatory bowel disease with a combination therapy of IL-23 and an antibody against TNF alpha
CA3142580A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
EP3976648A1 (en) 2019-06-03 2022-04-06 Janssen Biotech, Inc. Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
CA3145385A1 (en) 2019-07-08 2021-01-14 Steven D. Goodman Antibody compositions for disrupting biofilms
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
EP4077376A2 (en) 2019-12-19 2022-10-26 Quidel Corporation Monoclonal antibody fusions
BR112022011895A2 (en) 2019-12-20 2022-09-06 Basf Se DECREASE IN TERPENE TOXIDITY AND INCREASED POTENTIAL PRODUCTION IN MICROORGANISMS
IL295387A (en) 2020-02-05 2022-10-01 Larimar Therapeutics Inc Tat peptide binding proteins and uses thereof
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
US20210338833A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021245064A1 (en) 2020-06-04 2021-12-09 Isobionics B.V. Synthetic santalene synthases
EP4182466A2 (en) 2020-07-14 2023-05-24 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
WO2022029494A1 (en) 2020-08-04 2022-02-10 Abbott Rapid Diagnostics International Unlimited Company Assays for detecting sars-cov-2
EP4193149A1 (en) 2020-08-04 2023-06-14 Abbott Laboratories Improved methods and kits for detecting sars-cov-2 protein in a sample
CA3193594A1 (en) 2020-09-11 2022-03-17 Medimmune Limited Therapeutic b7-h4 binding molecules
CA3194182A1 (en) 2020-09-12 2022-03-17 Medimmune Limited A scoring method for an anti-b7h4 antibody-drug conjugate therapy
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
US20220170948A1 (en) 2020-12-01 2022-06-02 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
EP4015626A1 (en) 2020-12-18 2022-06-22 Isobionics B.V. Enzymes and methods for fermentative production of monoterpene esters
EP4271998A1 (en) 2020-12-30 2023-11-08 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
JP2024503657A (en) 2021-01-13 2024-01-26 メモリアル スローン-ケタリング キャンサー センター Antibody-pyrrolobenzodiazepine derivative conjugate
KR20230146522A (en) 2021-01-13 2023-10-19 메모리얼 슬로안 케터링 캔서 센터 Anti-DLL3 antibody-drug conjugate
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
CA3212729A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
AU2022232007A1 (en) 2021-03-12 2023-10-26 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
CN117203232A (en) 2021-03-17 2023-12-08 瑞塞普托斯有限责任公司 Methods of treating atopic dermatitis with anti-IL-13 antibodies
WO2022195028A2 (en) 2021-03-18 2022-09-22 Medimmune Limited Therapeutic binding molecules
EP4337689A1 (en) 2021-05-12 2024-03-20 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
CA3216320A1 (en) 2021-05-18 2022-11-24 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
AU2022276189A1 (en) 2021-05-20 2024-01-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
WO2022266034A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
US20230038355A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
WO2023281462A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
KR20240032991A (en) 2021-07-09 2024-03-12 얀센 바이오테크 인코포레이티드 Manufacturing Methods for Producing Anti-TNF Antibody Compositions
CN117795087A (en) 2021-08-02 2024-03-29 巴斯夫欧洲公司 Novel production of aromatic compounds with violet subunit ethane synthase
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
WO2023028186A1 (en) 2021-08-27 2023-03-02 Abbott Laboratories Methods for detecting immunoglobulin g, subclass 4 (igg4) in a biological sample
CA3230038A1 (en) 2021-08-31 2023-03-09 Hongwei Zhang Methods and systems of diagnosing brain injury
AU2022354059A1 (en) 2021-09-30 2024-03-28 Abbott Laboratories Methods and systems of diagnosing brain injury
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2023114978A1 (en) 2021-12-17 2023-06-22 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
US20230213536A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
TW202348252A (en) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 Combination therapies for treatment of cancer with therapeutic binding molecules
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024059692A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Hbv diagnostic, prognostic, and therapeutic methods and products
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4321365A (en) * 1977-10-19 1982-03-23 Research Corporation Oligonucleotides useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing adaptors and adapted molecules
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4293652A (en) * 1979-05-25 1981-10-06 Cetus Corporation Method for synthesizing DNA sequentially
US4271145A (en) * 1979-10-22 1981-06-02 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4879219A (en) * 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4362867A (en) * 1980-12-10 1982-12-07 Research Corporation Recombinant cDNA construction method and hybrid nucleotides useful in cloning
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4490358A (en) * 1982-03-01 1984-12-25 President And Fellows Of Harvard College Screening vaccines and immunization process
USRE32833E (en) * 1982-03-01 1989-01-17 President And Fellows Of Harvard College Screening vaccines and immunization process
US4366264A (en) 1982-04-16 1982-12-28 Stanley Wawzonek Use of calcium metasilicate (wollastonite) as a formaldehyde suppressant for urea formaldehyde resins
DE3300632A1 (en) * 1982-12-13 1984-07-12 Christian Dipl.-Ing. 8900 Augsburg Strobel Method of genetic analysis and synthesis
DE3246071A1 (en) * 1982-12-13 1984-06-14 Christian Dipl.-Ing. 8900 Augsburg Strobel Method of genetic analysis and synthesis
US4634678A (en) * 1982-12-13 1987-01-06 Molecular Genetics Research And Development Limited Partnership Plasmid cloning and expression vectors for use in microorganisms
DE3303173A1 (en) * 1982-12-13 1984-08-02 Christian Dipl.-Ing. 8900 Augsburg Strobel Method of genetic analysis and synthesis
US4719179A (en) * 1984-11-30 1988-01-12 Pharmacia P-L Biochemicals, Inc. Six base oligonucleotide linkers and methods for their use
US4959312A (en) * 1985-05-31 1990-09-25 The University Of Tennessee Research Corporation Full spectrum mutagenesis
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems

Also Published As

Publication number Publication date
GB2183661A (en) 1987-06-10
DE3588239T3 (en) 2007-03-08
US20040161816A1 (en) 2004-08-19
US6569641B1 (en) 2003-05-27
CH0229046H1 (en) 1998-07-15
DE3546807C2 (en) 1991-03-28
EP0590689B1 (en) 2002-05-22
EP1186660A3 (en) 2002-03-20
US5723323A (en) 1998-03-03
US5824514A (en) 1998-10-20
EP0590689A2 (en) 1994-04-06
GB2183661B (en) 1989-06-28
FR2579618A1 (en) 1986-10-03
IN169027B (en) 1991-08-17
DE3546806C2 (en) 1991-03-28
IN165561B (en) 1989-11-18
EP0590689B2 (en) 2006-08-16
AU4434585A (en) 1986-10-23
US5814476A (en) 1998-09-29
DE3588239T2 (en) 2003-01-02
EP0229046B1 (en) 1994-05-04
GB8628313D0 (en) 1986-12-31
HK20292A (en) 1992-03-27
JPS62502235A (en) 1987-09-03
EP0590689A3 (en) 1994-04-20
DE3590766C2 (en) 1991-01-10
JP2002325594A (en) 2002-11-12
CN86102090A (en) 1986-11-05
CA1341595C (en) 2009-04-28
EP1186660A2 (en) 2002-03-13
SG7992G (en) 1992-03-20
DE3587814D1 (en) 1994-06-09
DE3590766T (en) 1987-04-23
WO1986005803A1 (en) 1986-10-09
US5817483A (en) 1998-10-06
JP2004089197A (en) 2004-03-25
JP2584613B2 (en) 1997-02-26
DE229046T1 (en) 1987-12-17
EP0229046A1 (en) 1987-07-22
DE3588239D1 (en) 2002-06-27
JPH0856667A (en) 1996-03-05
DE3587814T2 (en) 1994-11-10
US5976862A (en) 1999-11-02
FR2579618B1 (en) 1987-12-24

Similar Documents

Publication Publication Date Title
CA1339937C (en) Procedure for obtaining dna, rna peptides, polypeptides, or proteins by recombinant dna techniques
US5763192A (en) Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
AU684510B2 (en) Method for selection of biologically active peptide sequences
Gartland et al. Two interconvertible forms of tryptophanyl sRNA in E. coli.
EP0230222A1 (en) Expression of HTLV-III gag-Gene
KR860001515B1 (en) Process of replication and translation of human pre-growth hormone
JPS58500589A (en) poliovirus cDNA
Strand et al. Structural proteins of mammalian oncogenic RNA viruses: immunological characterization of the p15 polypeptide of Rauscher murine virus
EP0632129B1 (en) Recombinant foamy virus vectors for medicinal and diagnostic uses, and processes for preparing recombinant foamy virus vectors
KR930000273B1 (en) Method for producing useful substances
JPH01160998A (en) Polypeptide
Wu et al. Hepatitis delta virus mutant: effect on RNA editing
Buchhagen et al. Chromatographic Separation and Antigenic Analysis of Proteins of the Oncornaviruses IV. Biochemical Typing of Murine Viral Proteins
Nilsson et al. Deletion mapping of a short polyoma virus middle T antigen segment important for transformation
Wells et al. Isolation and characterization of polyoma virus genomes with deletions between the origin of viral DNA replication and the site of initiation of translation in the early region
EP0655502A1 (en) Cho cells transformed with a recombinant plasmid expressing human secreting type thyroid peroxidase and preparation thereof
Hansen et al. BiZyme: a novel fusion protein-mediating selection of vaccinia virus recombinants by fluorescence and antibiotic resistance
Fox et al. Antigens produced by recombinant DNA technology.
Randerath et al. Tumor mitochondrial transfer RNAs: the nucleotide sequence of mitochondrial tRNALeuUAG from Morris hepatoma 5123D
RU2405824C1 (en) RECOMBINANT PLASMID pFastBAC-B17R DNA CONTAINING COWPOX VIRUS GENOME FRAGMENT CODING ALPHA/BETA-INTERFERON BINDING PROTEIN AND BvB17RG BACULOVIRUS STRAIN PRODUCING SOLUBLE ALPHA/BETA-INTERFERON BINDING PROTEIN OF COWPOX VIRUS
Shinnick et al. Peptide-elicited protein-reactive antibodies in molecular biology and medicine
Zhang et al. Cellular mobile genetic elements in the regulatory region of the pneumotropic mouse polyomavirus genome: structure and function in viral gene expression and DNA replication
CN117568369A (en) Protein system for rapidly screening binding with decoy RNA, method and application
CN116003624A (en) SIRT1 fusion proteins and uses thereof
CN116655798A (en) gp96-RBD fusion protein and application of related biological material thereof in activation of long-acting plasma cells

Legal Events

Date Code Title Description
MKEX Expiry

Effective date: 20150630